YASUHIROOKIYASUHIRO OKI9081OKI, YASUHIROAssociate Professorprns:coAuthorOfcoauthor ofFaculty Rankprns:fullNamefull nameprns:hasAuthorListauthor listprns:hasFacultyRankhas faculty rankprns:hasNetworkhas networkprns:hasPublicationVenuepublished inprns:informationResourceReferenceinformation resource referenceprns:isPrimaryPositionis primary positionprns:maxWeightmaximum weightprns:medlineTAjournal title abbreviationprns:meshDescriptorUIMeSH DescriptorUIprns:meshSemanticGroupNameMeSH semantic group nameprns:minWeightminimum weightprns:numberOfAuthorsnumber of authorsprns:numberOfConnectionsnumber of connectionsprns:numberOfPublicationsnumber of publicationsprns:personIdPerson IDprns:personInPrimaryPositionperson in primary positionprns:positionInDepartmentposition in departmentprns:positionInDivisionposition in divisionprns:predicateNodepredicate nodeprns:publicationDatepublication dateprns:similarTosimilar toprns:sortOrdersort orderprns:uniquenessWeightuniqueness weightprns:yearyearAcademic ArticleArticleDocumentbibo:pmidPubMed IdentifierAddressvivo:address1address line 1vivo:addressCitycityvivo:addressPostalCodepostal codevivo:addressStatestate or provincevivo:authorInAuthorshipselected publicationsvivo:authorRankauthor rank in publicationAuthorshipDepartmentDivisionvivo:hasResearchArearesearch areasvivo:hrJobTitleHR job titleInformation Resourcevivo:linkedAuthorlinked authorvivo:linkedInformationResourcelinked information resourcevivo:mailingAddressmailing addressvivo:personInPositionpositionsPositionvivo:positionInOrganizationposition in organizationvivo:preferredTitlepreferred titlerdf:predicatepredicaterdf:typetyperdfs:labellabelConceptAgentfoaf:firstNamefirst namefoaf:lastNamelast nameOrganizationPerson25445468Oki Y, Ewer MS, Lenihan DJ, Fisch MJ, Hagemeister FB, Fanale M, Romaguera J, Pro B, Fowler N, Younes A, Astrow AB, Huang X, Kwak LW, Samaniego F, McLaughlin P, Neelapu SS, Wang M, Fayad LE, Durand JB, Rodriguez MAClinical lymphoma, myeloma & leukemiaPegylated liposomal doxorubicin replacing conventional doxorubicin in standard R-CHOP chemotherapy for elderly patients with diffuse large B-cell lymphoma: an open label, single arm, phase II trial. Clin Lymphoma Myeloma Leuk. 2015 Mar; 15(3):152-8.Clin Lymphoma Myeloma Leuk2014-09-28T00:00:002014Pegylated liposomal doxorubicin replacing conventional doxorubicin in standard R-CHOP chemotherapy for elderly patients with diffuse large B-cell lymphoma: an open label, single arm, phase II trial.1400 Holcombe BlvdHouston77030-4008TXAuthorship 1735412Authorship 1741071Authorship 1763061Authorship 1765117Authorship 1770951Authorship 1782271Authorship 1790901Authorship 1794051Authorship 1799361Authorship 1827593Authorship 18513612Authorship 1854331Authorship 1871045Authorship 1924051Authorship 1929611Authorship 19444514Authorship 1946558Authorship 1948311Authorship 195918115270645Oki Y, Younes AExpert review of vaccinesHeat shock protein-based cancer vaccines. Expert Rev Vaccines. 2004 Aug; 3(4):403-11.Expert Rev Vaccines2004-08-01T00:00:002004Heat shock protein-based cancer vaccines.16037387Jelinek J, Oki Y, Gharibyan V, Bueso-Ramos C, Prchal JT, Verstovsek S, Beran M, Estey E, Kantarjian HM, Issa JPBloodJAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia. Blood. 2005 Nov 15; 106(10):3370-3.Blood2005-07-21T00:00:002005JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia.16123215Oki Y, Kantarjian HM, Zhou X, Cortes J, Faderl S, Verstovsek S, O'Brien S, Koller C, Beran M, Bekele BN, Pierce S, Thomas D, Ravandi F, Wierda WG, Giles F, Ferrajoli A, Jabbour E, Keating MJ, Bueso-Ramos CE, Estey E, Garcia-Manero GBloodAdult acute megakaryocytic leukemia: an analysis of 37 patients treated at M.D. Anderson Cancer Center. Blood. 2006 Feb 01; 107(3):880-4.Blood2005-08-25T00:00:002005Adult acute megakaryocytic leukemia: an analysis of 37 patients treated at M.D. Anderson Cancer Center.17023173Oki Y, Aoki E, Issa JPCritical reviews in oncology/hematologyDecitabine--bedside to bench. Crit Rev Oncol Hematol. 2007 Feb; 61(2):140-52.Crit Rev Oncol Hematol2006-10-04T00:00:002006Decitabine--bedside to bench.17296586Oki Y, Georgakis GV, Migone TS, Kwak LW, Younes AHaematologicaPrognostic significance of serum B-lymphocyte stimulator in Hodgkin's lymphoma. Haematologica. 2007 Feb; 92(2):269-70.Haematologica2007-02-01T00:00:002007Prognostic significance of serum B-lymphocyte stimulator in Hodgkin's lymphoma.17488651Oki Y, Younes AHaematologicaEndothelial progenitor cells in non-Hodgkin's lymphoma. Haematologica. 2007 Apr; 92(4):433-4.Haematologica2007-04-01T00:00:002007Endothelial progenitor cells in non-Hodgkin's lymphoma.18055336Oki Y, Issa JPInternational journal of hematologyTreatment options in advanced myelodysplastic syndrome, with emphasis on epigenetic therapy. Int J Hematol. 2007 Nov; 86(4):306-14.Int J Hematol2007-11-01T00:00:002007Treatment options in advanced myelodysplastic syndrome, with emphasis on epigenetic therapy.19737307Chihara D, Kagami Y, Oki Y, Kato H, Onoda H, Ine S, Taji H, Yamamoto K, Morishima YEuropean journal of haematologyR-CHOP therapy for MALT lymphoma of the rectum. Eur J Haematol. 2010 Jan 01; 84(1):84-6.Eur J Haematol2009-09-08T00:00:002009R-CHOP therapy for MALT lymphoma of the rectum.22816487Oki Y, Kondo Y, Yamamoto K, Ogura M, Kasai M, Kobayashi Y, Watanabe T, Uike N, Ohyashiki K, Okamoto S, Ohnishi K, Tomita A, Miyazaki Y, Tohyama K, Mukai HY, Hotta T, Tomonaga MCancer sciencePhase I/II study of decitabine in patients with myelodysplastic syndrome: a multi-center study in Japan. Cancer Sci. 2012 Oct; 103(10):1839-47.Cancer Sci2012-09-14T00:00:002012Phase I/II study of decitabine in patients with myelodysplastic syndrome: a multi-center study in Japan.23590726Oki Y, Younes A, Copeland A, Hagemeister F, Fayad LE, McLaughlin P, Shah J, Fowler N, Romaguera J, Kwak LW, Pro BBritish journal of haematologyPhase I study of vorinostat in combination with standard CHOP in patients with newly diagnosed peripheral T-cell lymphoma. Br J Haematol. 2013 Jul; 162(1):138-41.Br J Haematol2013-04-17T00:00:002013Phase I study of vorinostat in combination with standard CHOP in patients with newly diagnosed peripheral T-cell lymphoma.24117234Oki Y, Westin JR, Vega F, Chuang H, Fowler N, Neelapu S, Hagemeister FB, McLaughlin P, Kwak LW, Romaguera JE, Fanale M, Younes A, Rodriguez MA, Orlowski RZ, Wang M, Ouzounian ST, Samaniego F, Fayad LBritish journal of haematologyProspective phase II study of rituximab with alternating cycles of hyper-CVAD and high-dose methotrexate with cytarabine for young patients with high-risk diffuse large B-cell lymphoma. Br J Haematol. 2013 Dec; 163(5):611-20.Br J Haematol2013-10-01T00:00:002013Prospective phase II study of rituximab with alternating cycles of hyper-CVAD and high-dose methotrexate with cytarabine for young patients with high-risk diffuse large B-cell lymphoma.24386943Oki Y, Chuang H, Chasen B, Jessop A, Pan T, Fanale M, Dabaja B, Fowler N, Romaguera J, Fayad L, Hagemeister F, Rodriguez MA, Neelapu S, Samaniego F, Kwak L, Younes ABritish journal of haematologyThe prognostic value of interim positron emission tomography scan in patients with classical Hodgkin lymphoma. Br J Haematol. 2014 Apr; 165(1):112-6.Br J Haematol2014-01-06T00:00:002014The prognostic value of interim positron emission tomography scan in patients with classical Hodgkin lymphoma.24721592Dabaja BS, Hess K, Shihadeh F, Podoloff DA, Medeiros LJ, Mawlawi O, Arzu I, Oki Y, Hagemeister FB, Fayad LE, Reed VK, Kedir A, Wogan CF, Rodriguez AInternational journal of radiation oncology, biology, physicsPositron emission tomography/computed tomography findings during therapy predict outcome in patients with diffuse large B-cell lymphoma treated with chemotherapy alone but not in those who receive consolidation radiation. Int J Radiat Oncol Biol Phys. 2014 Jun 01; 89(2):384-91.Int J Radiat Oncol Biol Phys2014-04-07T00:00:002014Positron emission tomography/computed tomography findings during therapy predict outcome in patients with diffuse large B-cell lymphoma treated with chemotherapy alone but not in those who receive consolidation radiation.25042202Younes A, Thieblemont C, Morschhauser F, Flinn I, Friedberg JW, Amorim S, Hivert B, Westin J, Vermeulen J, Bandyopadhyay N, de Vries R, Balasubramanian S, Hellemans P, Smit JW, Fourneau N, Oki YThe Lancet. OncologyCombination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study. Lancet Oncol. 2014 Aug; 15(9):1019-26.Lancet Oncol2014-07-17T00:00:002014Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study.HematopathologyLeukemiaLymphoma-MyelomaRadiation OncologyMD AndersonLUIS EFAYADLUIS E FAYAD8618FAYAD, LUIS EAssociate ProfessorJORGE ECORTESJORGE E CORTES8637CORTES, JORGE EProfessorHAGOP MKANTARJIANHAGOP M KANTARJIAN8501KANTARJIAN, HAGOP MProfessorMICHELLE AFANALEMICHELLE A FANALE9015FANALE, MICHELLE AAssociate ProfessorBOUTHAINA SHBIBDABAJABOUTHAINA SHBIB DABAJA8729DABAJA, BOUTHAINA SHBIBProfessorL JEFFREYMEDEIROSL JEFFREY MEDEIROS8762MEDEIROS, L JEFFREYProfessor4.571640.00788647476research areas5.219660.018388118coauthor of351.45642.395960similar to11196selected publicationsELIAS JOSEPHJABBOURELIAS JOSEPH JABBOUR9124JABBOUR, ELIAS JOSEPHAssociate ProfessorGUILLERMOGARCIA-MANEROGUILLERMO GARCIA-MANERO8853GARCIA-MANERO, GUILLERMOProfessorJASON ROBERTWESTINJASON ROBERT WESTIN9367WESTIN, JASON ROBERTAssistant ProfessorNATHANFOWLERNATHAN FOWLER9439FOWLER, NATHANAssociate ProfessorAuthorship 2193243Authorship 2219442Authorship 2231542Authorship 2237411Authorship 2246711Authorship 2264937Authorship 2272731Authorship 2281275Authorship 2292362Authorship 2293671Authorship 2320841Authorship 2333458Authorship 2341571Authorship 234186511019850Kishi Y, Kami M, Oki Y, Kazuyama Y, Kawabata M, Miyakoshi S, Morinaga S, Suzuki R, Mori S, Muto YBone marrow transplantationDonor lymphocyte infusion for treatment of life-threatening respiratory syncytial virus infection following bone marrow transplantation. Bone Marrow Transplant. 2000 Sep; 26(5):573-6.Bone Marrow Transplant2000-09-01T00:00:002000Donor lymphocyte infusion for treatment of life-threatening respiratory syncytial virus infection following bone marrow transplantation.14615808Matsunaga N, Oki Y, Prigollini AThe New Zealand medical journalA case of QT-interval prolongation precipitated by azithromycin. N Z Med J. 2003 Nov 07; 116(1185):U666.N Z Med J2003-11-07T00:00:002003A case of QT-interval prolongation precipitated by azithromycin.15973667Oki Y, McLaughlin P, Pro B, Hagemeister FB, Bleyer A, Loyer E, Younes ACancerPhase II study of oxaliplatin in patients with recurrent or refractory non-Hodgkin lymphoma. Cancer. 2005 Aug 15; 104(4):781-7.Cancer2005-08-15T00:00:002005Phase II study of oxaliplatin in patients with recurrent or refractory non-Hodgkin lymphoma.16882708Kantarjian H, Oki Y, Garcia-Manero G, Huang X, O'Brien S, Cortes J, Faderl S, Bueso-Ramos C, Ravandi F, Estrov Z, Ferrajoli A, Wierda W, Shan J, Davis J, Giles F, Saba HI, Issa JPBloodResults of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood. 2007 Jan 01; 109(1):52-7.Blood2006-08-01T00:00:002006Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia.17991293Oki Y, Ogura M, Kato H, Kikuchi A, Taji H, Kagami Y, Oshiro A, Tsujimura A, Yamamoto K, Morishima YCancer sciencePhase II study of a salvage regimen using cyclophosphamide, high-dose cytarabine, dexamethasone, etoposide, and rituximab in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma. Cancer Sci. 2008 Jan; 99(1):179-84.Cancer Sci2007-11-07T00:00:002007Phase II study of a salvage regimen using cyclophosphamide, high-dose cytarabine, dexamethasone, etoposide, and rituximab in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma.18452104Oki Y, Younes ALeukemia & lymphomaCurrent role of gemcitabine in the treatment of Hodgkin lymphoma. Leuk Lymphoma. 2008 May; 49(5):883-9.Leuk Lymphoma2008-05-01T00:00:002008Current role of gemcitabine in the treatment of Hodgkin lymphoma.19470736Stewart DJ, Issa JP, Kurzrock R, Nunez MI, Jelinek J, Hong D, Oki Y, Guo Z, Gupta S, Wistuba IIClinical cancer research : an official journal of the American Association for Cancer ResearchDecitabine effect on tumor global DNA methylation and other parameters in a phase I trial in refractory solid tumors and lymphomas. Clin Cancer Res. 2009 Jun 01; 15(11):3881-8.Clin Cancer Res2009-05-26T00:00:002009Decitabine effect on tumor global DNA methylation and other parameters in a phase I trial in refractory solid tumors and lymphomas.19951884Kato H, Taji H, Ogura M, Kagami Y, Oki Y, Tsujimura A, Fuwa N, Kodaira T, Seto M, Yamamoto K, Morishima YClinical lymphoma & myelomaFavorable consolidative effect of high-dose melphalan and total-body irradiation followed by autologous peripheral blood stem cell transplantation after rituximab-containing induction chemotherapy with in vivo purging in relapsed or refractory follicular lymphoma. Clin Lymphoma Myeloma. 2009 Dec; 9(6):443-8.Clin Lymphoma Myeloma2009-12-01T00:00:002009Favorable consolidative effect of high-dose melphalan and total-body irradiation followed by autologous peripheral blood stem cell transplantation after rituximab-containing induction chemotherapy with in vivo purging in relapsed or refractory follicular lymphoma.20148943Chihara D, Oki Y, Ine S, Kato H, Onoda H, Taji H, Kagami Y, Yamamoto K, Morishima YEuropean journal of haematologyPrimary gastric diffuse large B-cell Lymphoma (DLBCL): analyses of prognostic factors and value of pretreatment FDG-PET scan. Eur J Haematol. 2010 Jun; 84(6):493-8.Eur J Haematol2010-02-09T00:00:002010Primary gastric diffuse large B-cell Lymphoma (DLBCL): analyses of prognostic factors and value of pretreatment FDG-PET scan.20306243Oki Y, Issa JPCancer treatment and researchEpigenetic mechanisms in AML - a target for therapy. Cancer Treat Res. 2010; 145:19-40.Cancer Treat Res2010-01-01T00:00:002010Epigenetic mechanisms in AML - a target for therapy.22428917Oki Y, Younes AExpert opinion on biological therapyBrentuximab vedotin in systemic T-cell lymphoma. Expert Opin Biol Ther. 2012 May; 12(5):623-32.Expert Opin Biol Ther2012-03-20T00:00:002012Brentuximab vedotin in systemic T-cell lymphoma.23488661Dabaja BS, Phan J, Mawlawi O, Medeiros LJ, Etzel C, Liang FW, Podoloff D, Oki Y, Hagemeister FB, Chuang H, Fayad LE, Westin JR, Shihadeh F, Allen PK, Wogan CF, Rodriguez MALeukemia & lymphomaClinical implications of positron emission tomography-negative residual computed tomography masses after chemotherapy for diffuse large B-cell lymphoma. Leuk Lymphoma. 2013 Dec; 54(12):2631-8.Leuk Lymphoma2013-05-07T00:00:002013Clinical implications of positron emission tomography-negative residual computed tomography masses after chemotherapy for diffuse large B-cell lymphoma.24097867Oki Y, Buglio D, Fanale M, Fayad L, Copeland A, Romaguera J, Kwak LW, Pro B, de Castro Faria S, Neelapu S, Fowler N, Hagemeister F, Zhang J, Zhou S, Feng L, Younes AClinical cancer research : an official journal of the American Association for Cancer ResearchPhase I study of panobinostat plus everolimus in patients with relapsed or refractory lymphoma. Clin Cancer Res. 2013 Dec 15; 19(24):6882-90.Clin Cancer Res2013-10-04T00:00:002013Phase I study of panobinostat plus everolimus in patients with relapsed or refractory lymphoma.24439229Leventaki V, Manning JT, Luthra R, Mehta P, Oki Y, Romaguera JE, Medeiros LJ, Vega FHuman pathologyIndolent peripheral T-cell lymphoma involving the gastrointestinal tract. Hum Pathol. 2014 Feb; 45(2):421-6.Hum Pathol2014-02-01T00:00:002014Indolent peripheral T-cell lymphoma involving the gastrointestinal tract.Authorship 2472871Authorship 2489961Authorship 2504271Authorship 2506011Authorship 2511791Authorship 2528351Authorship 2552831Authorship 2560772Authorship 2564275Authorship 2564902Authorship 2570371Authorship 2576344Authorship 2583011Authorship 2586422Authorship 2589572Authorship 2618671Authorship 262037216870548Oki Y, Jelinek J, Beran M, Verstovsek S, Kantarjian HM, Issa JPHaematologicaMutations and promoter methylation status of NPM1 in myeloproliferative disorders. Haematologica. 2006 Aug; 91(8):1147-8.Haematologica2006-07-25T00:00:002006Mutations and promoter methylation status of NPM1 in myeloproliferative disorders.17236224Oki Y, Kantarjian HM, Gharibyan V, Jones D, O'brien S, Verstovsek S, Cortes J, Morris GM, Garcia-Manero G, Issa JPCancerPhase II study of low-dose decitabine in combination with imatinib mesylate in patients with accelerated or myeloid blastic phase of chronic myelogenous leukemia. Cancer. 2007 Mar 01; 109(5):899-906.Cancer2007-03-01T00:00:002007Phase II study of low-dose decitabine in combination with imatinib mesylate in patients with accelerated or myeloid blastic phase of chronic myelogenous leukemia.17786728Oki Y, Georgakis GV, Migone TS, Kwak LW, Younes ALeukemia & lymphomaElevated serum BLyS levels in patients with non-Hodgkin lymphoma. Leuk Lymphoma. 2007 Sep; 48(9):1869-71.Leuk Lymphoma2007-09-01T00:00:002007Elevated serum BLyS levels in patients with non-Hodgkin lymphoma.18452099Oki Y, Kato H, Matsuo K, Kuwatsuka Y, Taji H, Yamamoto K, Kagami Y, Morishima YLeukemia & lymphomaPrognostic value of serum soluble interleukin-2 receptor level in patients with diffuse large B cell lymphoma, treated with CHOP- or RCHOP-based therapy. Leuk Lymphoma. 2008 Jul; 49(7):1345-51.Leuk Lymphoma2008-07-01T00:00:002008Prognostic value of serum soluble interleukin-2 receptor level in patients with diffuse large B cell lymphoma, treated with CHOP- or RCHOP-based therapy.18473969Oki Y, Issa JPReviews on recent clinical trialsReview: recent clinical trials in epigenetic therapy. Rev Recent Clin Trials. 2006 May; 1(2):169-82.Rev Recent Clin Trials2006-05-01T00:00:002006Review: recent clinical trials in epigenetic therapy.18691256Oki Y, Yamamoto K, Kato H, Kuwatsuka Y, Taji H, Kagami Y, Morishima YEuropean journal of haematologyLow absolute lymphocyte count is a poor prognostic marker in patients with diffuse large B-cell lymphoma and suggests patients' survival benefit from rituximab. Eur J Haematol. 2008 Dec; 81(6):448-53.Eur J Haematol2008-08-06T00:00:002008Low absolute lymphocyte count is a poor prognostic marker in patients with diffuse large B-cell lymphoma and suggests patients' survival benefit from rituximab.20490723Oki Y, Younes ACurrent hematologic malignancy reportsDoes rituximab have a place in treating classic hodgkin lymphoma? Curr Hematol Malig Rep. 2010 Jul; 5(3):135-9.Curr Hematol Malig Rep2010-07-01T00:00:002010Does rituximab have a place in treating classic hodgkin lymphoma?21378774Kato H, Kagami Y, Kodaira T, Oka S, Oki Y, Chihara D, Taji H, Yatabe Y, Nakamura T, Nakamura S, Seto M, Yamamoto K, Morishima YThe American journal of gastroenterologyNodal relapse after Helicobacter pylori eradication in a patient with primary localized gastric mucosa-associated lymphoid tissue lymphoma. Am J Gastroenterol. 2011 Mar; 106(3):549-51.Am J Gastroenterol2011-03-01T00:00:002011Nodal relapse after Helicobacter pylori eradication in a patient with primary localized gastric mucosa-associated lymphoid tissue lymphoma.21512731Chihara D, Oki Y, Onoda H, Taji H, Yamamoto K, Tamaki T, Morishima YInternational journal of hematologyHigh maximum standard uptake value (SUVmax) on PET scan is associated with shorter survival in patients with diffuse large B cell lymphoma. Int J Hematol. 2011 Apr; 93(4):502-508.Int J Hematol2011-04-06T00:00:002011High maximum standard uptake value (SUVmax) on PET scan is associated with shorter survival in patients with diffuse large B cell lymphoma.21668391Oki Y, Copeland A, Younes AExpert review of hematologyClinical development of panobinostat in classical Hodgkin's lymphoma. Expert Rev Hematol. 2011 Jun; 4(3):245-52.Expert Rev Hematol2011-06-01T00:00:002011Clinical development of panobinostat in classical Hodgkin's lymphoma.21745170Chihara D, Oki Y, Matsuo K, Onoda H, Taji H, Yamamoto K, Morishima YLeukemia & lymphomaIncidence and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: analyses with competing risk regression model. Leuk Lymphoma. 2011 Dec; 52(12):2270-5.Leuk Lymphoma2011-07-12T00:00:002011Incidence and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: analyses with competing risk regression model.21978956Kato H, Yamamoto K, Taji H, Oki Y, Chihara D, Seto M, Kagami Y, Morishima YClinical lymphoma, myeloma & leukemiaInterstitial pneumonia after autologous hematopoietic stem cell transplantation in B-cell non-hodgkin lymphoma. Clin Lymphoma Myeloma Leuk. 2011 Dec; 11(6):483-9.Clin Lymphoma Myeloma Leuk2011-10-05T00:00:002011Interstitial pneumonia after autologous hematopoietic stem cell transplantation in B-cell non-hodgkin lymphoma.21988665Oki Y, Copeland A, Romaguera J, Fayad L, Fanale M, Faria Sde C, Medeiros LJ, Ivy P, Younes ALeukemia & lymphomaClinical experience with the heat shock protein-90 inhibitor, tanespimycin, in patients with relapsed lymphoma. Leuk Lymphoma. 2012 May; 53(5):990-2.Leuk Lymphoma2012-03-13T00:00:002012Clinical experience with the heat shock protein-90 inhibitor, tanespimycin, in patients with relapsed lymphoma.22033282Younes A, Oki Y, Bociek RG, Kuruvilla J, Fanale M, Neelapu S, Copeland A, Buglio D, Galal A, Besterman J, Li Z, Drouin M, Patterson T, Ward MR, Paulus JK, Ji Y, Medeiros LJ, Martell REThe Lancet. OncologyMocetinostat for relapsed classical Hodgkin's lymphoma: an open-label, single-arm, phase 2 trial. Lancet Oncol. 2011 Dec; 12(13):1222-8.Lancet Oncol2011-10-25T00:00:002011Mocetinostat for relapsed classical Hodgkin's lymphoma: an open-label, single-arm, phase 2 trial.22371887Younes A, Oki Y, McLaughlin P, Copeland AR, Goy A, Pro B, Feng L, Yuan Y, Chuang HH, Macapinlac HA, Hagemeister F, Romaguera J, Samaniego F, Fanale MA, Dabaja BS, Rodriguez MA, Dang N, Kwak LW, Neelapu SS, Fayad LEBloodPhase 2 study of rituximab plus ABVD in patients with newly diagnosed classical Hodgkin lymphoma. Blood. 2012 May 03; 119(18):4123-8.Blood2012-02-27T00:00:002012Phase 2 study of rituximab plus ABVD in patients with newly diagnosed classical Hodgkin lymphoma.24329994Westin J, Oki Y, Fayad LBritish journal of haematologyCould treatment with R-HCVAD/R-MA as compared to R- CHOP truly result in improved outcomes for patients with high-risk diffuse large B cell lymphoma? - Response to Landsburg et?al. Br J Haematol. 2014 Apr; 165(1):146-7.Br J Haematol2013-12-16T00:00:002013Could treatment with R-HCVAD/R-MA as compared to R- CHOP truly result in improved outcomes for patients with high-risk diffuse large B cell lymphoma? - Response to Landsburg et?al.24943107Oki Y, Noorani M, Lin P, Davis RE, Neelapu SS, Ma L, Ahmed M, Rodriguez MA, Hagemeister FB, Fowler N, Wang M, Fanale MA, Nastoupil L, Samaniego F, Lee HJ, Dabaja BS, Pinnix CC, Medeiros LJ, Nieto Y, Khouri I, Kwak LW, Turturro F, Romaguera JE, Fayad LE, Westin JRBritish journal of haematologyDouble hit lymphoma: the MD Anderson Cancer Center clinical experience. Br J Haematol. 2014 Sep; 166(6):891-901.Br J Haematol2014-06-18T00:00:002014Double hit lymphoma: the MD Anderson Cancer Center clinical experience.Authorship 2676271Authorship 2683592Authorship 2714972Authorship 271988918085611Oki Y, Pro B, Fayad LE, Romaguera J, Samaniego F, Hagemeister F, Neelapu S, McLaughlin P, Goy A, Younes ACancerPhase 2 study of gemcitabine in combination with rituximab in patients with recurrent or refractory Hodgkin lymphoma. Cancer. 2008 Feb 15; 112(4):831-6.Cancer2008-02-15T00:00:002008Phase 2 study of gemcitabine in combination with rituximab in patients with recurrent or refractory Hodgkin lymphoma.19770379Wang M, Oki Y, Pro B, Romaguera JE, Rodriguez MA, Samaniego F, McLaughlin P, Hagemeister F, Neelapu S, Copeland A, Samuels BI, Loyer EM, Ji Y, Younes AJournal of clinical oncology : official journal of the American Society of Clinical OncologyPhase II study of yttrium-90-ibritumomab tiuxetan in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol. 2009 Nov 01; 27(31):5213-8.J Clin Oncol2009-09-21T00:00:002009Phase II study of yttrium-90-ibritumomab tiuxetan in patients with relapsed or refractory mantle cell lymphoma.23795711Armand P, Oki Y, Neuberg DS, Faham M, Cummings C, Klinger M, Weng L, Bhattar S, Lacasce AS, Jacobsen ED, Davids MS, Jacobson C, Fisher DC, Brown JR, Fowler NH, Alma Rodriguez M, Wallace MJ, Neelapu SS, Rodig S, Younes A, Freedman ASBritish journal of haematologyDetection of circulating tumour DNA in patients with aggressive B-cell non-Hodgkin lymphoma. Br J Haematol. 2013 Oct; 163(1):123-6.Br J Haematol2013-06-25T00:00:002013Detection of circulating tumour DNA in patients with aggressive B-cell non-Hodgkin lymphoma.24652992Horwitz SM, Advani RH, Bartlett NL, Jacobsen ED, Sharman JP, O'Connor OA, Siddiqi T, Kennedy DA, Oki YBloodObjective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin. Blood. 2014 May 15; 123(20):3095-100.Blood2014-03-20T00:00:002014Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin.Authorship 2735233Authorship 2737602Authorship 2743441Authorship 27511510Authorship 277059111023395Fruchter OThe New England journal of medicinePhiladelphia chromosome-positive acute lymphoblastic leukemia in children. N Engl J Med. 2000 Oct 05; 343(14):1043; author reply 1043-4.N Engl J Med2000-10-05T00:00:002000Philadelphia chromosome-positive acute lymphoblastic leukemia in children.17688495Huang X, Biswas S, Oki Y, Issa JP, Berry DABiometricsA parallel phase I/II clinical trial design for combination therapies. Biometrics. 2007 Jun; 63(2):429-36.Biometrics2007-06-01T00:00:002007A parallel phase I/II clinical trial design for combination therapies.19860627Chihara D, Oki Y, Ine S, Yamamoto K, Kato H, Taji H, Kagami Y, Yatabe Y, Nakamura S, Morishima YLeukemia & lymphomaAnalysis of prognostic factors in peripheral T-cell lymphoma: prognostic value of serum albumin and mediastinal lymphadenopathy. Leuk Lymphoma. 2009 Dec; 50(12):1999-2004.Leuk Lymphoma2009-12-01T00:00:002009Analysis of prognostic factors in peripheral T-cell lymphoma: prognostic value of serum albumin and mediastinal lymphadenopathy.22383790Oki Y, Copeland A, Hagemeister F, Fayad LE, Fanale M, Romaguera J, Younes ABloodExperience with obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist in patients with relapsed or refractory classical Hodgkin lymphoma. Blood. 2012 Mar 01; 119(9):2171-2.Blood2012-03-01T00:00:002012Experience with obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist in patients with relapsed or refractory classical Hodgkin lymphoma.25039868Westin JR, McLaughlin P, Romaguera J, Hagemeister FB, Pro B, Dang NH, Samaniego F, Rodriguez MA, Fayad L, Oki Y, Fanale M, Fowler N, Nastoupil L, Feng L, Loyer E, Younes ABritish journal of haematologyPaclitaxel, topotecan and rituximab: long term outcomes of an effective salvage programme for relapsed or refractory aggressive B-cell non-Hodgkin lymphoma. Br J Haematol. 2014 Oct; 167(2):177-84.Br J Haematol2014-07-08T00:00:002014Paclitaxel, topotecan and rituximab: long term outcomes of an effective salvage programme for relapsed or refractory aggressive B-cell non-Hodgkin lymphoma.Authorship 2789351Authorship 2871172Authorship 2910302Authorship 2927584Authorship 2927652Authorship 29301516Authorship 2935853Authorship 2946928Authorship 29552712Authorship 2961554Authorship 2961781Authorship 2961951Authorship 29675510Authorship 2983741Authorship 29870819Authorship 2999454Authorship 3000392Authorship 30157629Authorship 30233710Authorship 3036275Authorship 3048822Authorship 3054521623714549Fowler N, Oki YAmerican Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual MeetingDeveloping novel strategies to target B-cell malignancies. Am Soc Clin Oncol Educ Book. 2013; 366-72.Am Soc Clin Oncol Educ Book2013-01-01T00:00:002013Developing novel strategies to target B-cell malignancies.25200691Chihara D, Oki YExpert opinion on biological therapyBrentuximab vedotin for treatment of systemic T-cell lymphoma. Expert Opin Biol Ther. 2014 Oct; 14(10):1519-26.Expert Opin Biol Ther2014-09-02T00:00:002014Brentuximab vedotin for treatment of systemic T-cell lymphoma.25439689Fowler NH, Davis RE, Rawal S, Nastoupil L, Hagemeister FB, McLaughlin P, Kwak LW, Romaguera JE, Fanale MA, Fayad LE, Westin JR, Shah J, Orlowski RZ, Wang M, Turturro F, Oki Y, Claret LC, Feng L, Baladandayuthapani V, Muzzafar T, Tsai KY, Samaniego F, Neelapu SSThe Lancet. OncologySafety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial. Lancet Oncol. 2014 Nov; 15(12):1311-8.Lancet Oncol2014-10-15T00:00:002014Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial.25528252Hughes CL, Yorio JT, Kovitz C, Oki YJournal of medical case reportsTreatment decisions in a man with Hodgkin lymphoma and Guillian-Barr? syndrome: a case report. J Med Case Rep. 2014 Dec 21; 8:455.J Med Case Rep2014-12-21T00:00:002014Treatment decisions in a man with Hodgkin lymphoma and Guillian-Barr? syndrome: a case report.25529575Cheah CY, Oki Y, Westin JR, Turturro FBritish journal of haematologyA clinician's guide to double hit lymphomas. Br J Haematol. 2015 Mar; 168(6):784-95.Br J Haematol2014-12-22T00:00:002014A clinician's guide to double hit lymphomas.25573987Jacobsen ED, Sharman JP, Oki Y, Advani RH, Winter JN, Bello CM, Spitzer G, Palanca-Wessels MC, Kennedy DA, Levine P, Yang J, Bartlett NLBloodBrentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression. Blood. 2015 Feb 26; 125(9):1394-402.Blood2015-01-08T00:00:002015Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression.25754633Tao R, Allen PK, Rodriguez A, Shihadeh F, Pinnix CC, Arzu I, Reed VK, Oki Y, Westin JR, Fayad LE, Medeiros LJ, Dabaja BInternational journal of radiation oncology, biology, physicsBenefit of consolidative radiation therapy for primary bone diffuse large B-cell lymphoma. Int J Radiat Oncol Biol Phys. 2015 May 01; 92(1):122-9.Int J Radiat Oncol Biol Phys2015-03-05T00:00:002015Benefit of consolidative radiation therapy for primary bone diffuse large B-cell lymphoma.25809997Peng J, Zuo Z, Fu B, Oki Y, Tang G, Goswami M, Priyanka P, Muzzafar T, Medeiros LJ, Luthra R, Wang SAEuropean journal of haematologyChronic myelomonocytic leukemia with nucleophosmin (NPM1) mutation. Eur J Haematol. 2016 Jan; 96(1):65-71.Eur J Haematol2015-04-21T00:00:002015Chronic myelomonocytic leukemia with nucleophosmin (NPM1) mutation.25818067Oki Y, Neelapu SS, Fanale M, Kwak LW, Fayad L, Rodriguez MA, Wallace M, Klinger M, Carlton V, Kong K, Faham M, Younes ABritish journal of haematologyDetection of classical Hodgkin lymphoma specific sequence in peripheral blood using a next-generation sequencing approach. Br J Haematol. 2015 Jun; 169(5):689-93.Br J Haematol2015-03-29T00:00:002015Detection of classical Hodgkin lymphoma specific sequence in peripheral blood using a next-generation sequencing approach.25820332Oki Y, Younes A, Knickerbocker J, Samaniego F, Nastoupil L, Hagemeister F, Romaguera J, Fowler N, Kwak L, Westin JHaematologicaExperience with HSP90 inhibitor AUY922 in patients with relapsed or refractory non-Hodgkin lymphoma. Haematologica. 2015 Jul; 100(7):e272-4.Haematologica2015-03-27T00:00:002015Experience with HSP90 inhibitor AUY922 in patients with relapsed or refractory non-Hodgkin lymphoma.25863759Pinnix CC, Dabaja B, Ahmed MA, Chuang HH, Costelloe C, Wogan CF, Reed V, Romaguera JE, Neelapu S, Oki Y, Rodriguez MA, Fayad L, Hagemeister FB, Nastoupil L, Turturro F, Fowler N, Fanale MA, Nieto Y, Khouri IF, Ahmed S, Medeiros LJ, Davis RE, Westin JInternational journal of radiation oncology, biology, physicsSingle-institution experience in the treatment of primary mediastinal B cell lymphoma treated with immunochemotherapy in the setting of response assessment by 18fluorodeoxyglucose positron emission tomography. Int J Radiat Oncol Biol Phys. 2015 May 01; 92(1):113-21.Int J Radiat Oncol Biol Phys2015-05-01T00:00:002015Single-institution experience in the treatment of primary mediastinal B cell lymphoma treated with immunochemotherapy in the setting of response assessment by 18fluorodeoxyglucose positron emission tomography.25863764Pinnix CC, Smith GL, Milgrom S, Osborne EM, Reddy JP, Akhtari M, Reed V, Arzu I, Allen PK, Wogan CF, Fanale MA, Oki Y, Turturro F, Romaguera J, Fayad L, Fowler N, Westin J, Nastoupil L, Hagemeister FB, Rodriguez MA, Ahmed S, Nieto Y, Dabaja BInternational journal of radiation oncology, biology, physicsPredictors of radiation pneumonitis in patients receiving intensity modulated radiation therapy for Hodgkin and non-Hodgkin lymphoma. Int J Radiat Oncol Biol Phys. 2015 May 01; 92(1):175-82.Int J Radiat Oncol Biol Phys2015-05-01T00:00:002015Predictors of radiation pneumonitis in patients receiving intensity modulated radiation therapy for Hodgkin and non-Hodgkin lymphoma.25993211Cheah CY, Oki Y, Fanale MAAmerican Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual MeetingNovel treatments for T-cell lymphoma. Am Soc Clin Oncol Educ Book. 2015; e468-78.Am Soc Clin Oncol Educ Book2015-01-01T00:00:002015Novel treatments for T-cell lymphoma.25999447Cheah CY, Nastoupil LJ, Neelapu SS, Forbes SG, Oki Y, Fowler NHBloodLenalidomide, idelalisib, and rituximab are unacceptably toxic in patients with relapsed/refractory indolent lymphoma. Blood. 2015 May 21; 125(21):3357-9.Blood2015-05-21T00:00:002015Lenalidomide, idelalisib, and rituximab are unacceptably toxic in patients with relapsed/refractory indolent lymphoma.26071868Nieto Y, Valdez BC, Thall PF, Ahmed S, Jones RB, Hosing C, Popat U, Shpall EJ, Qazilbash M, Gulbis A, Anderlini P, Alousi A, Shah N, Bashir Q, Liu Y, Oki Y, Hagemeister F, Fanale M, Dabaja B, Pinnix C, Champlin R, Andersson BSBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationVorinostat Combined with High-Dose Gemcitabine, Busulfan, and Melphalan with Autologous Stem Cell Transplantation in Patients with Refractory Lymphomas. Biol Blood Marrow Transplant. 2015 Nov; 21(11):1914-20.Biol Blood Marrow Transplant2015-06-11T00:00:002015Vorinostat Combined with High-Dose Gemcitabine, Busulfan, and Melphalan with Autologous Stem Cell Transplantation in Patients with Refractory Lymphomas.26213141Oki Y, Fanale M, Romaguera J, Fayad L, Fowler N, Copeland A, Samaniego F, Kwak LW, Neelapu S, Wang M, Feng L, Younes ABritish journal of haematologyPhase II study of an AKT inhibitor MK2206 in patients with relapsed or refractory lymphoma. Br J Haematol. 2015 Nov; 171(4):463-70.Br J Haematol2015-07-27T00:00:002015Phase II study of an AKT inhibitor MK2206 in patients with relapsed or refractory lymphoma.26260306Chihara D, Pro B, Loghavi S, Miranda RN, Medeiros LJ, Fanale MA, Hagemeister FB, Fayad LE, Romaguera JE, Samaniego F, Neelapu SS, Younes A, Fowler NH, Rodriguez MA, Wang M, Kwak LW, McLaughlin P, Dang NH, Oki YBritish journal of haematologyPhase II study of HCVIDD/MA in patients with newly diagnosed peripheral T-cell lymphoma. Br J Haematol. 2015 Nov; 171(4):509-16.Br J Haematol2015-08-10T00:00:002015Phase II study of HCVIDD/MA in patients with newly diagnosed peripheral T-cell lymphoma.26358140Takahashi K, Sivina M, Hoellenriegel J, Oki Y, Hagemeister FB, Fayad L, Romaguera JE, Fowler N, Fanale MA, Kwak LW, Samaniego F, Neelapu S, Xiao L, Huang X, Kantarjian H, Keating MJ, Wierda W, Fu K, Chan WC, Vose JM, O'Brien S, Davis RE, Burger JABritish journal of haematologyCCL3 and CCL4 are biomarkers for B cell receptor pathway activation and prognostic serum markers in diffuse large B cell lymphoma. Br J Haematol. 2015 Dec; 171(5):726-35.Br J Haematol2015-09-11T00:00:002015CCL3 and CCL4 are biomarkers for B cell receptor pathway activation and prognostic serum markers in diffuse large B cell lymphoma.26377735Shimizu C, Oki Y, Mitani Y, Nakamura T, Nabeshima TBiological & pharmaceutical bulletinFactors Affecting Ethanol-Induced Conditioned Place Preference and Locomotor Sensitization in Mice. Biol Pharm Bull. 2015; 38(12):1935-45.Biol Pharm Bull2015-09-16T00:00:002015Factors Affecting Ethanol-Induced Conditioned Place Preference and Locomotor Sensitization in Mice.26628470Clemens MW, Medeiros LJ, Butler CE, Hunt KK, Fanale MA, Horwitz S, Weisenburger DD, Liu J, Morgan EA, Kanagal-Shamanna R, Parkash V, Ning J, Sohani AR, Ferry JA, Mehta-Shah N, Dogan A, Liu H, Thormann N, Di Napoli A, DiNapoli A, Lade S, Piccolini J, Reyes R, Williams T, McCarthy CM, Hanson SE, Nastoupil LJ, Gaur R, Oki Y, Young KH, Miranda RNJournal of clinical oncology : official journal of the American Society of Clinical OncologyComplete Surgical Excision Is Essential for the Management of Patients With Breast Implant-Associated Anaplastic Large-Cell Lymphoma. J Clin Oncol. 2016 Jan 10; 34(2):160-8.J Clin Oncol2015-11-30T00:00:002015Complete Surgical Excision Is Essential for the Management of Patients With Breast Implant-Associated Anaplastic Large-Cell Lymphoma.26640039Wang ML, Lee H, Chuang H, Wagner-Bartak N, Hagemeister F, Westin J, Fayad L, Samaniego F, Turturro F, Oki Y, Chen W, Badillo M, Nomie K, DeLa Rosa M, Zhao D, Lam L, Addison A, Zhang H, Young KH, Li S, Santos D, Medeiros LJ, Champlin R, Romaguera J, Zhang LThe Lancet. OncologyIbrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trial. Lancet Oncol. 2016 Jan; 17(1):48-56.Lancet Oncol2015-11-28T00:00:002015Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trial.74Professor10Assistant Professor14Associate Professor26795083Pinnix CC, Shah JJ, Chuang H, Costelloe CM, Medeiros LJ, Wogan CF, Reed V, Smith GL, Milgrom S, Patel K, Huo J, Turturro F, Romaguera J, Fayad L, Oki Y, Fanale MA, Westin J, Nastoupil L, Hagemeister FB, Rodriguez A, Qazilbash M, Shah N, Bashir Q, Ahmed S, Nieto Y, Hosing C, Rohren E, Dabaja BClinical lymphoma, myeloma & leukemiaDoxorubicin-Based Chemotherapy and Radiation Therapy Produces Favorable Outcomes in Limited-Stage Plasmablastic Lymphoma: A Single-Institution Review. Clin Lymphoma Myeloma Leuk. 2016 Mar; 16(3):122-8.Clin Lymphoma Myeloma Leuk2015-12-22T00:00:002015Doxorubicin-Based Chemotherapy and Radiation Therapy Produces Favorable Outcomes in Limited-Stage Plasmablastic Lymphoma: A Single-Institution Review.27064056Anderlini P, Saliba RM, Ledesma C, Plair T, Alousi AM, Hosing CM, Khouri IF, Nieto Y, Popat UR, Shpall EJ, Fanale MA, Hagemeister FB, Oki Y, Neelapu S, Romaguera JE, Younes A, Champlin REBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationGemcitabine, Fludarabine, and Melphalan for Reduced-Intensity Conditioning and Allogeneic Stem Cell?Transplantation for Relapsed and Refractory Hodgkin?Lymphoma. Biol Blood Marrow Transplant. 2016 07; 22(7):1333-1337.Biol Blood Marrow Transplant2016-04-06T00:00:002016Gemcitabine, Fludarabine, and Melphalan for Reduced-Intensity Conditioning and Allogeneic Stem Cell?Transplantation for Relapsed and Refractory Hodgkin?Lymphoma.27227654Pinnix CC, Osborne EM, Chihara D, Lai P, Zhou S, Ramirez MM, Oki Y, Hagemeister FB, Rodriguez AM, Samaniego F, Fowler N, Romaguera JE, Turturro F, Fayad L, Westin JR, Nastoupil L, Neelapu SS, Cheah CY, Dabaja BS, Milgrom SA, Smith GL, Horace P, Milbourne A, Wogan CF, Ballas L, Fanale MAJAMA oncologyMaternal and Fetal Outcomes After Therapy for Hodgkin or Non-Hodgkin Lymphoma Diagnosed During Pregnancy. JAMA Oncol. 2016 Aug 01; 2(8):1065-9.JAMA Oncol2016-08-01T00:00:002016Maternal and Fetal Outcomes After Therapy for Hodgkin or Non-Hodgkin Lymphoma Diagnosed During Pregnancy.17133412Oki Y, McLaughlin P, Fayad LE, Pro B, Mansfield PF, Clayman GL, Medeiros LJ, Kwak LW, Srivastava PK, Younes ACancerExperience with heat shock protein-peptide complex 96 vaccine therapy in patients with indolent non-Hodgkin lymphoma. Cancer. 2007 Jan 01; 109(1):77-83.Cancer2007-01-01T00:00:002007Experience with heat shock protein-peptide complex 96 vaccine therapy in patients with indolent non-Hodgkin lymphoma.16707430Shu J, Jelinek J, Chang H, Shen L, Qin T, Chung W, Oki Y, Issa JPCancer researchSilencing of bidirectional promoters by DNA methylation in tumorigenesis. Cancer Res. 2006 May 15; 66(10):5077-84.Cancer Res2006-05-15T00:00:002006Silencing of bidirectional promoters by DNA methylation in tumorigenesis.20038729Shen L, Kantarjian H, Guo Y, Lin E, Shan J, Huang X, Berry D, Ahmed S, Zhu W, Pierce S, Kondo Y, Oki Y, Jelinek J, Saba H, Estey E, Issa JPJournal of clinical oncology : official journal of the American Society of Clinical OncologyDNA methylation predicts survival and response to therapy in patients with myelodysplastic syndromes. J Clin Oncol. 2010 Feb 01; 28(4):605-13.J Clin Oncol2009-12-28T00:00:002009DNA methylation predicts survival and response to therapy in patients with myelodysplastic syndromes.20716667Est?cio MR, Gallegos J, Vallot C, Castoro RJ, Chung W, Maegawa S, Oki Y, Kondo Y, Jelinek J, Shen L, Hartung H, Aplan PD, Czerniak BA, Liang S, Issa JPGenome researchGenome architecture marked by retrotransposons modulates predisposition to DNA methylation in cancer. Genome Res. 2010 Oct; 20(10):1369-82.Genome Res2010-08-17T00:00:002010Genome architecture marked by retrotransposons modulates predisposition to DNA methylation in cancer.Authorship 841123Authorship 842088Authorship 842104Authorship 844802Authorship 844823Authorship 846611Authorship 847564Authorship 848204Authorship 848737Authorship 848855Authorship 848996Authorship 850045Authorship 851201Authorship 851866Authorship 853807Authorship 854791Authorship 855274Authorship 856159Authorship 858112Authorship 858216Authorship 862022Authorship 862980Authorship 863566Authorship 863740Authorship 864170Authorship 864255Authorship 864864Authorship 865138Authorship 865257Authorship 866909Journal of Clinical OncologyComplete surgical excision is essential for the management of patients with breast implant-associated anaplastic large-cell lymphoma. Journal of Clinical Oncology. 34:160-168.Complete surgical excision is essential for the management of patients with breast implant-associated anaplastic large-cell lymphomaBritish Journal of HaematologyDose adjusted-EPOCH-R and mediastinal disease may improve outcomes for patients with gray-zone lymphoma. British Journal of Haematology. Dose adjusted-EPOCH-R and mediastinal disease may improve outcomes for patients with gray-zone lymphomaAmerican Journal of Hematology/ OncologyThe role of gemcitabine and rituximab in the management of relapsed or refractory hodgkin lymphoma. American Journal of Hematology/ Oncology. 7.The role of gemcitabine and rituximab in the management of relapsed or refractory hodgkin lymphomaBlood Cancer JournalImmune regulatory effects of panobinostat in patients with Hodgkin lymphoma through modulation of serum cytokine levels and T-cell PD1 expression. Blood Cancer Journal. 4.Immune regulatory effects of panobinostat in patients with Hodgkin lymphoma through modulation of serum cytokine levels and T-cell PD1 expressionBiology of Blood and Marrow TransplantationGemcitabine, Fludarabine, and Melphalan for Reduced-Intensity Conditioning and Allogeneic Stem Cell Transplantation for Relapsed and Refractory Hodgkin Lymphoma. Biology of Blood and Marrow Transplantation. Gemcitabine, Fludarabine, and Melphalan for Reduced-Intensity Conditioning and Allogeneic Stem Cell Transplantation for Relapsed and Refractory Hodgkin LymphomaAnnals of OncologyAllogeneic stem-cell transplantation in patients with cutaneous lymphoma. Annals of Oncology. 26:2490-2495.Allogeneic stem-cell transplantation in patients with cutaneous lymphomaModern PathologyP53 expression correlates with poorer survival and augments the negative prognostic effect of MYC rearrangement, expression or concurrent MYC/BCL2 expression in diffuse large B-cell lymphoma. Modern Pathology. P53 expression correlates with poorer survival and augments the negative prognostic effect of MYC rearrangement, expression or concurrent MYC/BCL2 expression in diffuse large B-cell lymphomaHaematologicaExperience with HSP90 inhibitor AUY922 in patients with relapsed or refractory non-Hodgkin lymphoma. Haematologica. 100:e272-e274.Experience with HSP90 inhibitor AUY922 in patients with relapsed or refractory non-Hodgkin lymphomaBritish Journal of HaematologyThe survival outcome of patients with relapsed/refractory peripheral T-cell lymphoma-not otherwise specified and angioimmunoblastic T-cell lymphoma. British Journal of Haematology. The survival outcome of patients with relapsed/refractory peripheral T-cell lymphoma-not otherwise specified and angioimmunoblastic T-cell lymphomaBritish Journal of HaematologyDose-Adjusted EPOCH-R and Mid-Cycle High Dose Methotrexate for Patients with Systemic Lymphoma and secondary CNS Involvement. British Journal of Haematology. Dose-Adjusted EPOCH-R and Mid-Cycle High Dose Methotrexate for Patients with Systemic Lymphoma and secondary CNS InvolvementInternational Journal of Radiation Oncology Biology PhysicsChemotherapy Response Assessment by FDG-PET-CT in Early-stage Classical Hodgkin Lymphoma. International Journal of Radiation Oncology Biology Physics. 97:333-338.Chemotherapy Response Assessment by FDG-PET-CT in Early-stage Classical Hodgkin LymphomaHuman PathologyHuman Pathology. 60:160-166.Human PathologyClinical Lymphoma, Myeloma and LeukemiaDoxorubicin-Based Chemotherapy and Radiation Therapy Produces Favorable Outcomes in Limited-Stage Plasmablastic Lymphoma. Clinical Lymphoma, Myeloma and Leukemia. 16:122-128.Doxorubicin-Based Chemotherapy and Radiation Therapy Produces Favorable Outcomes in Limited-Stage Plasmablastic LymphomaInternational Journal of Radiation Oncology Biology PhysicsDoes Bleomycin Lung Toxicity Increase the Risk of Radiation Pneumonitis in Hodgkin Lymphoma?. International Journal of Radiation Oncology Biology Physics. 96:951-958.Does Bleomycin Lung Toxicity Increase the Risk of Radiation Pneumonitis in Hodgkin Lymphoma?Dermatology Online JournalAtypical lymphoproliferative disorder-clinical and pathological features. Dermatology Online Journal. 22.Atypical lymphoproliferative disorder-clinical and pathological featuresBloodResults of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia [2]. Blood. 108:4291-4292.Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia [2]British Journal of HaematologyPhase II study of HCVIDD/MA in patients with newly diagnosed peripheral T-cell lymphoma. British Journal of Haematology. Phase II study of HCVIDD/MA in patients with newly diagnosed peripheral T-cell lymphomaBiology of Blood and Marrow TransplantationVorinostat Combined with High-Dose Gemcitabine, Busulfan, and Melphalan with Autologous Stem Cell Transplantation in Patients with Refractory Lymphomas. Biology of Blood and Marrow Transplantation. 21:1914-1920.Vorinostat Combined with High-Dose Gemcitabine, Busulfan, and Melphalan with Autologous Stem Cell Transplantation in Patients with Refractory LymphomasMedical Journal of AustraliaEmbolisation to the fingers of both hands from aortic atheroma. Medical Journal of Australia. 180:31.Embolisation to the fingers of both hands from aortic atheromaEuropean Journal of HaematologyChronic myelomonocytic leukemia with nucleophosmin (NPM1) mutation. European Journal of Haematology. Chronic myelomonocytic leukemia with nucleophosmin (NPM1) mutationLeukemiaErratum. Leukemia. 27:1792.ErratumBritish Journal of HaematologyPrognostic significance of baseline peripheral absolute neutrophil, monocyte and serum β2-microglobulin level in patients with diffuse large b-cell lymphoma. British Journal of Haematology. 175:290-299.Prognostic significance of baseline peripheral absolute neutrophil, monocyte and serum β2-microglobulin level in patients with diffuse large b-cell lymphomaThe Lancet OncologySafety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma. The Lancet Oncology. Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myelomaAnnals of OncologyFactors influencing outcome in advanced stage, low-grade follicular lymphoma treated at MD Anderson Cancer Center in the rituximab era. Annals of Oncology. 27:895-901.Factors influencing outcome in advanced stage, low-grade follicular lymphoma treated at MD Anderson Cancer Center in the rituximab eraBritish Journal of HaematologyPhase II study of an AKT inhibitor MK2206 in patients with relapsed or refractory lymphoma. British Journal of Haematology. Phase II study of an AKT inhibitor MK2206 in patients with relapsed or refractory lymphomaLeukemia and LymphomaBrentuximab vedotin activity in diffuse large B-cell lymphoma with CD30 undetectable by visual assessment of conventional immunohistochemistry. Leukemia and Lymphoma. 1-10.Brentuximab vedotin activity in diffuse large B-cell lymphoma with CD30 undetectable by visual assessment of conventional immunohistochemistryThe Lancet OncologyIbrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma. The Lancet Oncology. Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphomaLeukemia and LymphomaIfosfamide, carboplatin, etoposide with or without bortezomib in patients with relapsed/refractory Hodgkin lymphoma. Leukemia and Lymphoma. Ifosfamide, carboplatin, etoposide with or without bortezomib in patients with relapsed/refractory Hodgkin lymphomaAnnals of OncologyPatients with classical Hodgkin lymphoma experiencing disease progression after treatment with brentuximab vedotin have poor outcomes. Annals of Oncology. 27:1317-1323.Patients with classical Hodgkin lymphoma experiencing disease progression after treatment with brentuximab vedotin have poor outcomesBritish Journal of HaematologyCCL3 and CCL4 are biomarkers for B cell receptor pathway activation and prognostic serum markers in diffuse large B cell lymphoma. British Journal of Haematology. 171:726-735.CCL3 and CCL4 are biomarkers for B cell receptor pathway activation and prognostic serum markers in diffuse large B cell lymphoma18055864Oki Y, Jelinek J, Shen L, Kantarjian HM, Issa JPBloodInduction of hypomethylation and molecular response after decitabine therapy in patients with chronic myelomonocytic leukemia. Blood. 2008 Feb 15; 111(4):2382-4.Blood2007-11-30T00:00:002007Induction of hypomethylation and molecular response after decitabine therapy in patients with chronic myelomonocytic leukemia.29622656Strati P, Chihara D, Oki Y, Fayad LE, Fowler N, Nastoupil L, Romaguera JE, Samaniego F, Garg N, Feng L, Wesson ET, Ruben CE, Stafford MD, Nieto Y, Khouri IF, Hosing C, Horowitz SB, Kamble RT, Fanale MAHaematologicaA phase I study of romidepsin and ifosfamide, carboplatin, etoposide for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma. Haematologica. 2018 09; 103(9):e416-e418.Haematologica2018-04-05T00:00:002018A phase I study of romidepsin and ifosfamide, carboplatin, etoposide for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma.Authorship 88728415Authorship 8884347Authorship 88956513Authorship 8902453D016403Disorders27716600.457373Lymphoma, Large B-Cell, DiffuseD000971Procedures1259158060.204622Antineoplastic Combined Chemotherapy ProtocolsD016411Disorders631810.851779Lymphoma, T-Cell, PeripheralD008228Disorders27210400.616933Lymphoma, Non-HodgkinD006689Disorders32614290.523234Hodgkin DiseaseAuthorship 9023847Authorship 90426223Authorship 90574311Authorship 9057683Authorship 9063348Authorship 9067945Authorship 90716417Authorship 90802521Authorship 90904517Authorship 90950615Authorship 9096516Authorship 91155416Authorship 9122193Authorship 9122832Authorship 91260511Authorship 91286617Authorship 9129793Authorship 91300716Authorship 9143579Authorship 9145274Authorship 9145869Authorship 91481611Authorship 91538117Authorship 9154602Authorship 9160002Authorship 9172869Authorship 9190224Authorship 91955611Authorship 9196201Authorship 91999617Authorship 92007815Authorship 92150414Authorship 92273718Authorship 92287515Authorship 9228896Authorship 9233717Authorship 9234373Authorship 92370715Authorship 92399410Authorship 92418912Authorship 92433319Authorship 92536818Authorship 92572512Authorship 92600615Authorship 92706817Authorship 9270962Authorship 9271915Authorship 92721711Authorship 92779517Authorship 9279506Authorship 9293572Authorship 9297452Authorship 92984010Authorship 9302653Authorship 9325995Authorship 9352793Authorship 9359712Authorship 9364486Authorship 9365688Authorship 9371512Authorship 9371968Authorship 939189325804933Karuturi M, Younes A, Fayad L, Kwak L, Pro B, Shah J, Oki Y, Simien R, Liboon MJ, Hutto T, Feng L, Horowitz S, Nieto Y, Anderlini P, Alousi A, Popat U, Medeiros LJ, Miranda R, Fanale MLeukemia & lymphomaIfosfamide, carboplatin, etoposide with or without bortezomib in patients with relapsed/refractory Hodgkin lymphoma: results of a randomized phase II trial. Leuk Lymphoma. 2016 Feb; 57(2):445-447.Leuk Lymphoma2015-03-25T00:00:002015Ifosfamide, carboplatin, etoposide with or without bortezomib in patients with relapsed/refractory Hodgkin lymphoma: results of a randomized phase II trial.26872013Yabe M, Medeiros LJ, Tang G, Wang SA, Ahmed S, Nieto Y, Hu S, Bhagat G, Oki Y, Patel KP, Routbort M, Luthra R, Fanale MA, Bueso-Ramos CE, Jorgensen JL, Vega F, Chen W, Hoehn D, Konoplev S, Milton DR, Wistuba I, Li S, You MJ, Young KH, Miranda RNThe American journal of surgical pathologyPrognostic Factors of Hepatosplenic T-cell Lymphoma: Clinicopathologic Study of 28 Cases. Am J Surg Pathol. 2016 May; 40(5):676-88.Am J Surg Pathol2016-05-01T00:00:002016Prognostic Factors of Hepatosplenic T-cell Lymphoma: Clinicopathologic Study of 28 Cases.26873565Kim SJ, Yoon DH, Jaccard A, Chng WJ, Lim ST, Hong H, Park Y, Chang KM, Maeda Y, Ishida F, Shin DY, Kim JS, Jeong SH, Yang DH, Jo JC, Lee GW, Choi CW, Lee WS, Chen TY, Kim K, Jung SH, Murayama T, Oki Y, Advani R, d'Amore F, Schmitz N, Suh C, Suzuki R, Kwong YL, Lin TY, Kim WSThe Lancet. OncologyA prognostic index for natural killer cell lymphoma after non-anthracycline-based treatment: a multicentre, retrospective analysis. Lancet Oncol. 2016 Mar; 17(3):389-400.Lancet Oncol2016-02-10T00:00:002016A prognostic index for natural killer cell lymphoma after non-anthracycline-based treatment: a multicentre, retrospective analysis.27378601Chihara D, Westin JR, Miranda RN, Cheah CY, Oki Y, Turturro F, Romaguera JE, Neelapu SS, Nastoupil LJ, Fayad LE, Rodriguez MA, Fowler NH, Orlowski RZ, Wang M, Hagemeister FB, Medeiros LJ, Fanale MABritish journal of haematologyDose adjusted-EPOCH-R and mediastinal disease may improve outcomes for patients with gray-zone lymphoma. Br J Haematol. 2017 11; 179(3):503-506.Br J Haematol2016-07-05T00:00:002016Dose adjusted-EPOCH-R and mediastinal disease may improve outcomes for patients with gray-zone lymphoma.27222367Cheah CY, Br?ckelmann PJ, Chihara D, Moskowitz AJ, Engert A, Jerkeman M, El-Galaly TC, Augustson B, Vose J, Bartlett NL, Villa D, Connors JM, Feldman T, Pinnix CC, Milgrom SA, Dabaja B, Oki Y, Fanale MAAmerican journal of hematologyClinical characteristics and outcomes of patients with Hodgkin lymphoma with central nervous system involvement: An international multicenter collaboration. Am J Hematol. 2016 09; 91(9):894-9.Am J Hematol2016-06-20T00:00:002016Clinical characteristics and outcomes of patients with Hodgkin lymphoma with central nervous system involvement: An international multicenter collaboration.27448187Chen Y, Neelapu S, Feng L, Bi W, Yang TH, Wang M, Fanale MA, Westin JR, Hagemeister FB, Fayad LE, Romaguera JE, Samaniego F, Turturro F, Fowler NH, McLaughlin P, Cabanillas F, Oki Y, Nastoupil LJ, Rodriguez ABritish journal of haematologyPrognostic significance of baseline peripheral absolute neutrophil, monocyte and serum ?2-microglobulin level in patients with diffuse large b-cell lymphoma: a new prognostic model. Br J Haematol. 2016 Oct; 175(2):290-299.Br J Haematol2016-07-22T00:00:002016Prognostic significance of baseline peripheral absolute neutrophil, monocyte and serum ?2-microglobulin level in patients with diffuse large b-cell lymphoma: a new prognostic model.27502933Chihara D, Fowler NH, Oki Y, Fanale MA, Fayad LE, Westin JR, Hagemeister FBBritish journal of haematologyDose-Adjusted EPOCH-R and Mid-Cycle High Dose Methotrexate for Patients with Systemic Lymphoma and secondary CNS Involvement. Br J Haematol. 2017 12; 179(5):851-854.Br J Haematol2016-08-09T00:00:002016Dose-Adjusted EPOCH-R and Mid-Cycle High Dose Methotrexate for Patients with Systemic Lymphoma and secondary CNS Involvement.27203405Nieto Y, Valdez BC, Thall PF, Jones RB, Wei W, Myers A, Hosing C, Ahmed S, Popat U, Shpall EJ, Qazilbash M, Gulbis A, Anderlini P, Shah N, Bashir Q, Alousi A, Oki Y, Fanale M, Dabaja B, Pinnix C, Champlin R, Andersson BSCancerDouble epigenetic modulation of high-dose chemotherapy with azacitidine and vorinostat for patients with refractory or poor-risk relapsed lymphoma. Cancer. 2016 09 01; 122(17):2680-8.Cancer2016-05-20T00:00:002016Double epigenetic modulation of high-dose chemotherapy with azacitidine and vorinostat for patients with refractory or poor-risk relapsed lymphoma.27351173Chihara D, Westin JR, Oki Y, Ahmed MA, Do B, Fayad LE, Hagemeister FB, Romaguera JE, Fanale MA, Lee HJ, Turturro F, Samaniego F, Neelapu SS, Rodriguez MA, Fowler NH, Wang M, Davis RE, Nastoupil LJCancerManagement strategies and outcomes for very elderly patients with diffuse large B-cell lymphoma. Cancer. 2016 Oct 15; 122(20):3145-3151.Cancer2016-06-28T00:00:002016Management strategies and outcomes for very elderly patients with diffuse large B-cell lymphoma.27049457Younes A, Berdeja JG, Patel MR, Flinn I, Gerecitano JF, Neelapu SS, Kelly KR, Copeland AR, Akins A, Clancy MS, Gong L, Wang J, Ma A, Viner JL, Oki YThe Lancet. OncologySafety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial. Lancet Oncol. 2016 05; 17(5):622-31.Lancet Oncol2016-03-31T00:00:002016Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial.27742539Abou Yehia Z, Mikhaeel GN, Smith G, Pinnix CC, Milgrom SA, Tang C, Jiang W, Fanale MA, Oki Y, Shank JH, Horace T, Reddy J, Akhtari M, Gunther JR, Suki T, Allen PK, Turner S, Mawlawi O, Dabaja BSInternational journal of radiation oncology, biology, physicsDoes Bleomycin Lung Toxicity Increase the Risk of Radiation Pneumonitis in Hodgkin Lymphoma? Int J Radiat Oncol Biol Phys. 2016 12 01; 96(5):951-958.Int J Radiat Oncol Biol Phys2016-08-22T00:00:002016Does Bleomycin Lung Toxicity Increase the Risk of Radiation Pneumonitis in Hodgkin Lymphoma?27816715Xu J, Oki Y, Saksena A, Desai P, Lin P, Tang G, Yin CC, You MJ, Thakral B, Medeiros LJ, Li SHuman pathologyCD30 expression and prognostic significance in R-EPOCH-treated patients with diffuse large B-cell lymphoma. Hum Pathol. 2017 02; 60:160-166.Hum Pathol2016-11-02T00:00:002016CD30 expression and prognostic significance in R-EPOCH-treated patients with diffuse large B-cell lymphoma.27983760Chihara D, Fanale MA, Miranda RN, Noorani M, Westin JR, Nastoupil LJ, Hagemeister FB, Fayad LE, Romaguera JE, Samaniego F, Turturro F, Lee HJ, Neelapu SS, Rodriguez MA, Wang M, Fowler NH, Davis RE, Medeiros LJ, Hosing C, Nieto YL, Oki YBritish journal of haematologyThe survival outcome of patients with relapsed/refractory peripheral T-cell lymphoma-not otherwise specified and angioimmunoblastic T-cell lymphoma. Br J Haematol. 2017 03; 176(5):750-758.Br J Haematol2016-12-16T00:00:002016The survival outcome of patients with relapsed/refractory peripheral T-cell lymphoma-not otherwise specified and angioimmunoblastic T-cell lymphoma.27984652Milgrom SA, Jauhari S, Plastaras JP, Nieto Y, Dabaja BS, Pinnix CC, Smith GL, Allen PK, Lukens JN, Maity A, Oki Y, Fanale MA, Nasta SDCancerA multi-institutional analysis of peritransplantation radiotherapy in patients with relapsed/refractory Hodgkin lymphoma undergoing autologous stem cell transplantation. Cancer. 2017 Apr 15; 123(8):1363-1371.Cancer2016-12-16T00:00:002016A multi-institutional analysis of peritransplantation radiotherapy in patients with relapsed/refractory Hodgkin lymphoma undergoing autologous stem cell transplantation.28068241Milgrom SA, Dong W, Akhtari M, Smith GL, Pinnix CC, Mawlawi O, Rohren E, Garg N, Chuang H, Yehia ZA, Reddy JP, Gunther JR, Khoury JD, Suki T, Osborne EM, Oki Y, Fanale M, Dabaja BSInternational journal of radiation oncology, biology, physicsChemotherapy Response Assessment by FDG-PET-CT in Early-stage Classical Hodgkin Lymphoma: Moving Beyond the Five-Point Deauville Score. Int J Radiat Oncol Biol Phys. 2017 02 01; 97(2):333-338.Int J Radiat Oncol Biol Phys2016-10-22T00:00:002016Chemotherapy Response Assessment by FDG-PET-CT in Early-stage Classical Hodgkin Lymphoma: Moving Beyond the Five-Point Deauville Score.27739436Wang XJ, Bueso-Ramos CE, Tang G, Wang S, Oki Y, Desai P, Khoury JD, Miranda RN, Tang Z, Reddy N, Li SModern pathology : an official journal of the United States and Canadian Academy of Pathology, IncP53 expression correlates with poorer survival and augments the negative prognostic effect of MYC rearrangement, expression or concurrent MYC/BCL2 expression in diffuse large B-cell lymphoma. Mod Pathol. 2017 02; 30(2):194-203.Mod Pathol2016-10-14T00:00:002016P53 expression correlates with poorer survival and augments the negative prognostic effect of MYC rearrangement, expression or concurrent MYC/BCL2 expression in diffuse large B-cell lymphoma.27868471Bartlett NL, Smith MR, Siddiqi T, Advani RH, O'Connor OA, Sharman JP, Feldman T, Savage KJ, Shustov AR, Diefenbach CS, Oki Y, Palanca-Wessels MC, Uttarwar M, Li M, Yang J, Jacobsen EDLeukemia & lymphomaBrentuximab vedotin activity in diffuse large B-cell lymphoma with CD30 undetectable by visual assessment of conventional immunohistochemistry. Leuk Lymphoma. 2017 07; 58(7):1607-1616.Leuk Lymphoma2016-11-20T00:00:002016Brentuximab vedotin activity in diffuse large B-cell lymphoma with CD30 undetectable by visual assessment of conventional immunohistochemistry.28057167Shimizu C, Oki Y, Mitani Y, Tsuchiya Y, Nabeshima TJournal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiquesModerate-dose Regular Lifelong Alcohol Intake Changes the Intestinal Flora, Protects against Aging, and Keeps Spatial Memory in the Senescence-accelerated Mouse Prone 8 (SAMP8) Model. J Pharm Pharm Sci. 2016 Oct - Dec; 19(4):430-447.J Pharm Pharm Sci2016-10-01T00:00:002016Moderate-dose Regular Lifelong Alcohol Intake Changes the Intestinal Flora, Protects against Aging, and Keeps Spatial Memory in the Senescence-accelerated Mouse Prone 8 (SAMP8) Model.28039906Thakral B, Medeiros LJ, Desai P, Lin P, Yin CC, Tang G, Khoury JD, Hu S, Xu J, Loghavi S, Hu B, Oki Y, Li SEuropean journal of haematologyPrognostic impact of CD5 expression in diffuse large B-cell lymphoma in patients treated with rituximab-EPOCH. Eur J Haematol. 2017 Apr; 98(4):415-421.Eur J Haematol2017-01-30T00:00:002017Prognostic impact of CD5 expression in diffuse large B-cell lymphoma in patients treated with rituximab-EPOCH.28370694Pinnix CC, Dabaja BS, Milgrom SA, Smith GL, Abou Z, Nastoupil L, Romaguera J, Turturro F, Fowler N, Fayad L, Westin J, Neelapu S, Fanale MA, Rodriguez MA, Hagemeister F, Lee HJ, Oki Y, Wang M, Samaniego F, Chi L, Esmaeli BHead & neckUltra-low-dose radiotherapy for definitive management of ocular adnexal B-cell lymphoma. Head Neck. 2017 06; 39(6):1095-1100.Head Neck2017-04-03T00:00:002017Ultra-low-dose radiotherapy for definitive management of ocular adnexal B-cell lymphoma.28382648Jain P, Milgrom SA, Patel KP, Nastoupil L, Fayad L, Wang M, Pinnix CC, Dabaja BS, Smith GL, Yu J, Hu S, Bueso Ramos CE, Kanagal-Shamanna R, Medeiros LJ, Oki Y, Fowler NBritish journal of haematologyCharacteristics, management, and outcomes of patients with follicular dendritic cell sarcoma. Br J Haematol. 2017 08; 178(3):403-412.Br J Haematol2017-04-06T00:00:002017Characteristics, management, and outcomes of patients with follicular dendritic cell sarcoma.28482717Ho JC, Dabaja BS, Milgrom SA, Smith GL, Reddy JP, Mazloom A, Young KH, Deng L, Medeiros LJ, Dong W, Allen PK, Andraos TY, Fowler NH, Nastoupil LJ, Oki Y, Fayad LE, Turturro F, Neelapu SS, Westin J, Hagemeister FB, Rodriguez MA, Pinnix CCLeukemia & lymphomaRadiation therapy improves survival in patients with testicular diffuse large B-cell lymphoma<sup/>. Leuk Lymphoma. 2017 12; 58(12):2833-2844.Leuk Lymphoma2017-05-09T00:00:002017Radiation therapy improves survival in patients with testicular diffuse large B-cell lymphoma<sup/>.28340281Nastoupil LJ, McLaughlin P, Feng L, Neelapu SS, Samaniego F, Hagemeister FB, Ayala A, Romaguera JE, Goy AH, Neal E, Wang M, Fayad L, Fanale MA, Oki Y, Westin JR, Rodriguez MA, Cabanillas F, Fowler NHBritish journal of haematologyHigh ten-year remission rates following rituximab, fludarabine, mitoxantrone and dexamethasone (R-FND) with interferon maintenance in indolent lymphoma: Results of a randomized Study. Br J Haematol. 2017 04; 177(2):263-270.Br J Haematol2017-03-24T00:00:002017High ten-year remission rates following rituximab, fludarabine, mitoxantrone and dexamethasone (R-FND) with interferon maintenance in indolent lymphoma: Results of a randomized Study.28408615Lee HJ, Romaguera JE, Feng L, Desai AP, Zhang L, Fanale M, Samaniego F, Hagemeister FB, Fayad LE, Rodriguez MA, Medeiros JL, Hartig K, Nomie K, Ahmed M, Badillo M, Ye H, Oki Y, Lin P, Nastoupil L, Westin J, Wang MThe oncologistPhase II Study of Bortezomib in Combination with Cyclophosphamide and Rituximab for Relapsed or Refractory Mantle Cell Lymphoma. Oncologist. 2017 05; 22(5):549-553.Oncologist2017-04-13T00:00:002017Phase II Study of Bortezomib in Combination with Cyclophosphamide and Rituximab for Relapsed or Refractory Mantle Cell Lymphoma.28522441Fanale MA, Cheah CY, Rich A, Medeiros LJ, Lai CM, Oki Y, Romaguera JE, Fayad LE, Hagemeister FB, Samaniego F, Rodriguez MA, Neelapu SS, Lee HJ, Nastoupil L, Fowler NH, Turturro F, Westin JR, Wang ML, McLaughlin P, Pinnix CC, Milgrom SA, Dabaja B, Horowitz SB, Younes ABloodEncouraging activity for R-CHOP in advanced stage nodular lymphocyte-predominant Hodgkin lymphoma. Blood. 2017 07 27; 130(4):472-477.Blood2017-05-18T00:00:002017Encouraging activity for R-CHOP in advanced stage nodular lymphocyte-predominant Hodgkin lymphoma.28329608Wilmas K, Duvic M, Oki YDermatology online journalAtypical lymphoproliferative disorder-clinical and pathological features. Dermatol Online J. 2016 Sep 15; 22(9).Dermatol Online J2016-09-15T00:00:002016Atypical lymphoproliferative disorder-clinical and pathological features.28860342Oki Y, Kelly KR, Flinn I, Patel MR, Gharavi R, Ma A, Parker J, Hafeez A, Tuck D, Younes AHaematologicaCUDC-907 in relapsed/refractory diffuse large B-cell lymphoma, including patients with MYC-alterations: results from an expanded phase I trial. Haematologica. 2017 11; 102(11):1923-1930.Haematologica2017-08-31T00:00:002017CUDC-907 in relapsed/refractory diffuse large B-cell lymphoma, including patients with MYC-alterations: results from an expanded phase I trial.28792260Hu B, Younes A, Westin JR, Turturro F, Claret L, Feng L, Fowler N, Neelapu S, Romaguera J, Hagemeister FB, Rodriguez MA, Samaniego F, Fayad LE, Copeland AR, Nastoupil LJ, Nieto Y, Fanale MA, Oki YLeukemia & lymphomaPhase-I and randomized phase-II trial of panobinostat in combination with ICE (ifosfamide, carboplatin, etoposide) in relapsed or refractory classical Hodgkin lymphoma. Leuk Lymphoma. 2018 04; 59(4):863-870.Leuk Lymphoma2017-08-09T00:00:002017Phase-I and randomized phase-II trial of panobinostat in combination with ICE (ifosfamide, carboplatin, etoposide) in relapsed or refractory classical Hodgkin lymphoma.28844401Sugiyama K, Kawanishi S, Oki Y, Kamiya M, Hanada R, Egi M, Akai SBioorganic & medicinal chemistryLipase-catalyzed asymmetric synthesis of naphtho[2,3-c]furan-1(3H)-one derivatives by a one-pot dynamic kinetic resolution/intramolecular Diels-Alder reaction: Total synthesis of (-)-himbacine. Bioorg Med Chem. 2018 04 01; 26(7):1378-1386.Bioorg Med Chem2017-08-16T00:00:002017Lipase-catalyzed asymmetric synthesis of naphtho[2,3-c]furan-1(3H)-one derivatives by a one-pot dynamic kinetic resolution/intramolecular Diels-Alder reaction: Total synthesis of (-)-himbacine.29114604Smith GL, Duvic M, Yehia ZA, Allen P, Garg N, Suki T, Milgrom SA, Pinnix CC, Oki Y, Khoury JD, Dabaja BSAdvances in radiation oncologyEffectiveness of low-dose radiation for primary cutaneous anaplastic large cell lymphoma. Adv Radiat Oncol. 2017 Jul-Sep; 2(3):363-369.Adv Radiat Oncol2017-06-15T00:00:002017Effectiveness of low-dose radiation for primary cutaneous anaplastic large cell lymphoma.29114605Pinnix CC, Andraos TY, Dabaja B, Milgrom S, Smith G, Chihara D, Ng A, Fayad LE, Oki Y, Neelapu S, Westin J, Rodriguez MA, Nastoupil LJAdvances in radiation oncologyDiffuse large B-cell lymphoma in very elderly patients over 80 years old: Incorporating consolidative radiation therapy into management decisions. Adv Radiat Oncol. 2017 Jul-Sep; 2(3):370-380.Adv Radiat Oncol2017-04-22T00:00:002017Diffuse large B-cell lymphoma in very elderly patients over 80 years old: Incorporating consolidative radiation therapy into management decisions.29233821Horwitz SM, Koch R, Porcu P, Oki Y, Moskowitz A, Perez M, Myskowski P, Officer A, Jaffe JD, Morrow SN, Allen K, Douglas M, Stern H, Sweeney J, Kelly P, Kelly V, Aster JC, Weaver D, Foss FM, Weinstock DMBloodActivity of the PI3K-d,? inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma. Blood. 2018 02 22; 131(8):888-898.Blood2017-12-12T00:00:002017Activity of the PI3K-d,? inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma.28771675Jain P, Kanagal-Shamanna R, San Lucas FA, Nastoupil L, Romaguera J, Fayad L, Oki Y, Westin JR, Medeiros LJ, Wang M, Fowler NBritish journal of haematologyClinicopathological characteristics, outcomes and pattern of mutations in patients with follicular lymphoma who progressed on Bruton tyrosine kinase inhibitors. Br J Haematol. 2018 09; 182(5):718-723.Br J Haematol2017-08-02T00:00:002017Clinicopathological characteristics, outcomes and pattern of mutations in patients with follicular lymphoma who progressed on Bruton tyrosine kinase inhibitors.28832956Milgrom SA, Pinnix CC, Chuang H, Oki Y, Akhtari M, Mawlawi O, Garg N, Gunther JR, Reddy JP, Smith GL, Rohren E, Hagemeister FB, Lee HJ, Fayad LE, Dong W, Osborne EM, Abou Yehia Z, Fanale M, Dabaja BSBritish journal of haematologyEarly-stage Hodgkin lymphoma outcomes after combined modality therapy according to the post-chemotherapy 5-point score: can residual pet-positive disease be cured with radiotherapy alone? Br J Haematol. 2017 11; 179(3):488-496.Br J Haematol2017-08-18T00:00:002017Early-stage Hodgkin lymphoma outcomes after combined modality therapy according to the post-chemotherapy 5-point score: can residual pet-positive disease be cured with radiotherapy alone?29038339Akhtari M, Milgrom SA, Pinnix CC, Reddy JP, Dong W, Smith GL, Mawlawi O, Abou Yehia Z, Gunther J, Osborne EM, Andraos TY, Wogan CF, Rohren E, Garg N, Chuang H, Khoury JD, Oki Y, Fanale M, Dabaja BSBloodReclassifying patients with early-stage Hodgkin lymphoma based on functional radiographic markers at presentation. Blood. 2018 01 04; 131(1):84-94.Blood2017-10-16T00:00:002017Reclassifying patients with early-stage Hodgkin lymphoma based on functional radiographic markers at presentation.29191916Flinn IW, O'Brien S, Kahl B, Patel M, Oki Y, Foss FF, Porcu P, Jones J, Burger JA, Jain N, Kelly VM, Allen K, Douglas M, Sweeney J, Kelly P, Horwitz SBloodDuvelisib, a novel oral dual inhibitor of PI3K-d,?, is clinically active in advanced hematologic malignancies. Blood. 2018 02 22; 131(8):877-887.Blood2017-11-30T00:00:002017Duvelisib, a novel oral dual inhibitor of PI3K-d,?, is clinically active in advanced hematologic malignancies.29196178Strati P, Fowler N, Pina-Oviedo S, Medeiros LJ, Overman MJ, Romaguera JE, Nastoupil L, Wang M, Hagemeister FB, Rodriguez A, Oki Y, Westin J, Turturro F, Neelapu SS, Fayad LClinical lymphoma, myeloma & leukemiaLong-Term Remissions of Patients With Follicular Lymphoma Grade 3 Treated With R-CHOP. Clin Lymphoma Myeloma Leuk. 2018 01; 18(1):e103-e108.Clin Lymphoma Myeloma Leuk2017-11-14T00:00:002017Long-Term Remissions of Patients With Follicular Lymphoma Grade 3 Treated With R-CHOP.29538376Chihara D, Fanale MA, Miranda RN, Noorani M, Westin JR, Nastoupil LJ, Hagemeister FB, Fayad LE, Romaguera JE, Samaniego F, Turturro F, Lee HJ, Neelapu SS, Rodriguez MA, Wang M, Fowler NH, Davis RE, Medeiros LJ, Oki YPloS oneThe risk of central nervous system relapses in patients with peripheral T-cell lymphoma. PLoS One. 2018; 13(3):e0191461.PLoS One2018-03-14T00:00:002018The risk of central nervous system relapses in patients with peripheral T-cell lymphoma.29697005Ludmir EB, Milgrom SA, Pinnix CC, Gunther JR, Westin J, Oki Y, Fayad LE, Medeiros LJ, Dabaja BS, Nastoupil LJLeukemia & lymphomaPrimary breast diffuse large B-cell lymphoma: treatment strategies and patterns of failure<sup/>. Leuk Lymphoma. 2018 12; 59(12):2896-2903.Leuk Lymphoma2018-04-26T00:00:002018Primary breast diffuse large B-cell lymphoma: treatment strategies and patterns of failure<sup/>.29374824Chihara D, Oki YCurrent hematologic malignancy reportsCentral Nervous System Involvement in Peripheral T Cell Lymphoma. Curr Hematol Malig Rep. 2018 02; 13(1):1-6.Curr Hematol Malig Rep2018-02-01T00:00:002018Central Nervous System Involvement in Peripheral T Cell Lymphoma.29452771Milgrom SA, Pinnix CC, Chi TL, Vu TH, Gunther JR, Sheu T, Fowler N, Westin JR, Nastoupil LJ, Oki Y, Fayad LE, Neelapu S, Rodriguez MA, Hagemeister FB, Fanale MA, Lee HJ, Hosing C, Ahmed S, Nieto Y, Shpall EJ, Dabaja BSInternational journal of radiation oncology, biology, physicsRadiation Therapy as an Effective Salvage Strategy for Secondary CNS Lymphoma. Int J Radiat Oncol Biol Phys. 2018 04 01; 100(5):1146-1154.Int J Radiat Oncol Biol Phys2018-01-06T00:00:002018Radiation Therapy as an Effective Salvage Strategy for Secondary CNS Lymphoma.29681481Pinnix CC, Cella L, Andraos TY, Ayoub Z, Milgrom SA, Gunther J, Thosani S, Wogan C, Conson M, D'Avino V, Oki Y, Fanale M, Lee HJ, Neelapu S, Fayad L, Hagemeister F, Rodriguez MA, Nastoupil LJ, Nieto Y, Qiao W, Pacelli R, Dabaja BInternational journal of radiation oncology, biology, physicsPredictors of Hypothyroidism in Hodgkin Lymphoma Survivors After Intensity Modulated Versus 3-Dimensional Radiation Therapy. Int J Radiat Oncol Biol Phys. 2018 07 01; 101(3):530-540.Int J Radiat Oncol Biol Phys2018-03-14T00:00:002018Predictors of Hypothyroidism in Hodgkin Lymphoma Survivors After Intensity Modulated Versus 3-Dimensional Radiation Therapy.29851218Pinnix CC, Dabaja BS, Milgrom SA, Smith GL, Abou Z, Nastoupil L, Romaguera J, Turturro F, Fowler N, Fayad L, Westin J, Neelapu S, Fanale MA, Rodriguez MA, Hagemeister F, Ju Lee H, Oki Y, Wang M, Samaniego F, Chi L, Esmaeli BHead & neckUltra-low-dose radiotherapy for definitive management of ocular adnexal B-cell lymphoma. Head Neck. 2018 06; 40(6):1335.Head Neck2018-02-21T00:00:002018Ultra-low-dose radiotherapy for definitive management of ocular adnexal B-cell lymphoma.29224502Connors JM, Jurczak W, Straus DJ, Ansell SM, Kim WS, Gallamini A, Younes A, Alekseev S, Ill?s ?, Picardi M, Lech-Maranda E, Oki Y, Feldman T, Smolewski P, Savage KJ, Bartlett NL, Walewski J, Chen R, Ramchandren R, Zinzani PL, Cunningham D, Rosta A, Josephson NC, Song E, Sachs J, Liu R, Jolin HA, Huebner D, Radford J, ECHELON-1 Study GroupThe New England journal of medicineBrentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma. N Engl J Med. 2018 01 25; 378(4):331-344.N Engl J Med2017-12-10T00:00:002017Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma.29501779Nieto Y, Thall PF, Ma J, Valdez BC, Ahmed S, Anderlini P, Popat U, Jones RB, Shpall EJ, Hosing C, Qazilbash M, Kebriaei P, Alousi A, Timmons M, Gulbis A, Myers A, Oki Y, Fanale M, Dabaja B, Pinnix C, Milgrom S, Champlin R, Andersson BSBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationPhase II Trial of High-Dose Gemcitabine/Busulfan/Melphalan with Autologous Stem Cell Transplantation for Primary Refractory or Poor-Risk Relapsed Hodgkin Lymphoma. Biol Blood Marrow Transplant. 2018 08; 24(8):1602-1609.Biol Blood Marrow Transplant2018-03-02T00:00:002018Phase II Trial of High-Dose Gemcitabine/Busulfan/Melphalan with Autologous Stem Cell Transplantation for Primary Refractory or Poor-Risk Relapsed Hodgkin Lymphoma.29723393Romaguera JE, Wang M, Feng L, Fayad LE, Hagemeister F, McLaughlin P, Rodriguez MA, Fanale M, Orlowski R, Kwak LW, Neelapu S, Oki Y, Pro B, Younes A, Samaniego F, Fowler N, Hartig K, Valentinetti M, Smith J, Ford P, Naig A, Medeiros LJ, Kantarjian HM, Goy ACancerPhase 2 trial of bortezomib in combination with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with bortezomib, rituximab, methotrexate, and cytarabine for untreated mantle cell lymphoma. Cancer. 2018 06 15; 124(12):2561-2569.Cancer2018-05-03T00:00:002018Phase 2 trial of bortezomib in combination with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with bortezomib, rituximab, methotrexate, and cytarabine for untreated mantle cell lymphoma.29271057Reddy JP, Hernandez M, Gunther JR, Dabaja BS, Martin GV, Jiang W, Akhtari M, Allen PK, Atkinson BJ, Smith GL, Pinnix CC, Milgrom SA, Abou Yehia Z, Osborne EM, Oki Y, Lee H, Hagemeister F, Fanale MABritish journal of haematologyPre-treatment neutrophil/lymphocyte ratio and platelet/lymphocyte ratio are prognostic of progression in early stage classical Hodgkin lymphoma. Br J Haematol. 2018 02; 180(4):545-549.Br J Haematol2017-12-21T00:00:002017Pre-treatment neutrophil/lymphocyte ratio and platelet/lymphocyte ratio are prognostic of progression in early stage classical Hodgkin lymphoma.29277360Brammer JE, Chihara D, Poon LM, Caimi P, de Lima M, Ledesma C, Rondon G, Ciurea SO, Nieto Y, Fanale M, Dabaja B, Maziarz RT, Champlin RE, Hosing C, Oki YClinical lymphoma, myeloma & leukemiaManagement of Advanced and Relapsed/Refractory Extranodal Natural Killer T-Cell Lymphoma: An Analysis of Stem Cell Transplantation and Chemotherapy Outcomes. Clin Lymphoma Myeloma Leuk. 2018 01; 18(1):e41-e50.Clin Lymphoma Myeloma Leuk2017-10-12T00:00:002017Management of Advanced and Relapsed/Refractory Extranodal Natural Killer T-Cell Lymphoma: An Analysis of Stem Cell Transplantation and Chemotherapy Outcomes.29761078Hu B, Oki YFrontiers in oncologyNovel Immunotherapy Options for Extranodal NK/T-Cell Lymphoma. Front Oncol. 2018; 8:139.Front Oncol2018-04-30T00:00:002018Novel Immunotherapy Options for Extranodal NK/T-Cell Lymphoma.30209819Chihara D, Wong S, Feldman T, Fanale MA, Sanchez L, Connors JM, Savage KJ, Oki YHematological oncologyOutcome of patients with relapsed or refractory anaplastic large cell lymphoma who have failed brentuximab vedotin. Hematol Oncol. 2019 Feb; 37(1):35-38.Hematol Oncol2018-10-23T00:00:002018Outcome of patients with relapsed or refractory anaplastic large cell lymphoma who have failed brentuximab vedotin.29988979Chihara D, Fowler NH, Oki Y, Fanale MA, Nastoupil LJ, Westin JR, Fayad LE, Neelapu SS, Cheah CYOncotargetImpact of histologic subtypes and treatment modality among patients with primary central nervous system lymphoma: a SEER database analysis. Oncotarget. 2018 Jun 22; 9(48):28897-28902.Oncotarget2018-06-22T00:00:002018Impact of histologic subtypes and treatment modality among patients with primary central nervous system lymphoma: a SEER database analysis.30190343Strati P, Fanale MA, Oki Y, Turturro F, Fayad LE, Bartlett NL, Gladstone DE, Kasamon YL, Portlock CS, Wilson WH, Goy A, Younes A, Lee HJHaematologicaABVD plus rituximab versus ABVD alone for advanced stage, high-risk classical Hodgkin lymphoma: a randomized phase 2 study. Haematologica. 2019 02; 104(2):e65-e67.Haematologica2018-09-06T00:00:002018ABVD plus rituximab versus ABVD alone for advanced stage, high-risk classical Hodgkin lymphoma: a randomized phase 2 study.30202805Pinnix CC, Huo J, Milgrom SA, Yehia ZA, Fanale M, Oki Y, Dabaja BS, Smith GLAdvances in radiation oncologyUsing benchmarked lung radiation dose constraints to predict pneumonitis risk: Developing a nomogram for patients with mediastinal lymphoma. Adv Radiat Oncol. 2018 Jul-Sep; 3(3):372-381.Adv Radiat Oncol2018-04-24T00:00:002018Using benchmarked lung radiation dose constraints to predict pneumonitis risk: Developing a nomogram for patients with mediastinal lymphoma.29785017Huang W, Medeiros LJ, Lin P, Wang W, Tang G, Khoury J, Konoplev S, Yin CC, Xu J, Oki Y, Li SModern pathology : an official journal of the United States and Canadian Academy of Pathology, IncMYC/BCL2/BCL6 triple hit lymphoma: a study of 40 patients with a comparison to MYC/BCL2 and MYC/BCL6 double hit lymphomas. Mod Pathol. 2018 09; 31(9):1470-1478.Mod Pathol2018-05-21T00:00:002018MYC/BCL2/BCL6 triple hit lymphoma: a study of 40 patients with a comparison to MYC/BCL2 and MYC/BCL6 double hit lymphomas.29895624Pinnix CC, Ng AK, Dabaja BS, Milgrom SA, Gunther JR, Fuller CD, Smith GL, Abou Yehia Z, Qiao W, Wogan CF, Akhtari M, Mawlawi O, Medeiros LJ, Chuang HH, Martin-Doyle W, Armand P, LaCasce AS, Oki Y, Fanale M, Westin J, Neelapu S, Nastoupil LBlood advancesPositron emission tomography-computed tomography predictors of progression after DA-R-EPOCH for PMBCL. Blood Adv. 2018 06 12; 2(11):1334-1343.Blood Adv2018-06-12T00:00:002018Positron emission tomography-computed tomography predictors of progression after DA-R-EPOCH for PMBCL.29978452Chihara D, Oki Y, Fanale MA, Westin JR, Nastoupil LJ, Neelapu S, Fayad L, Fowler NH, Cheah CYBritish journal of haematologyStage I Non-Hodgkin Lymphoma: difference in survival outcome by primary extranodal site of involvement. Br J Haematol. 2019 04; 185(2):334-338.Br J Haematol2018-07-05T00:00:002018Stage I Non-Hodgkin Lymphoma: difference in survival outcome by primary extranodal site of involvement.30108156Liang WS, Vergilio JA, Salhia B, Huang HJ, Oki Y, Garrido-Laguna I, Park H, Westin JR, Meric-Bernstam F, Fabrizio D, Miller VA, Stephens PJ, Fanale MA, Ross JS, Janku FThe oncologistComprehensive Genomic Profiling of Hodgkin Lymphoma Reveals Recurrently Mutated Genes and Increased Mutation Burden. Oncologist. 2019 02; 24(2):219-228.Oncologist2018-08-14T00:00:002018Comprehensive Genomic Profiling of Hodgkin Lymphoma Reveals Recurrently Mutated Genes and Increased Mutation Burden.29704286Moustafa GAI, Oki Y, Akai SAngewandte Chemie (International ed. in English)Lipase-Catalyzed Dynamic Kinetic Resolution of C1 - and C2 -Symmetric Racemic Axially Chiral 2,2'-Dihydroxy-1,1'-biaryls. Angew Chem Int Ed Engl. 2018 08 06; 57(32):10278-10282.Angew Chem Int Ed Engl2018-05-25T00:00:002018Lipase-Catalyzed Dynamic Kinetic Resolution of C1 - and C2 -Symmetric Racemic Axially Chiral 2,2'-Dihydroxy-1,1'-biaryls.30033575Flinn IW, Patel M, Oki Y, Horwitz S, Foss FF, Allen K, Douglas M, Stern H, Sweeney J, Kharidia J, Kelly P, Kelly VM, Kahl BAmerican journal of hematologyDuvelisib, an oral dual PI3K-d, ? inhibitor, shows clinical activity in indolent non-Hodgkin lymphoma in a phase 1 study. Am J Hematol. 2018 11; 93(11):1311-1317.Am J Hematol2018-08-31T00:00:002018Duvelisib, an oral dual PI3K-d, ? inhibitor, shows clinical activity in indolent non-Hodgkin lymphoma in a phase 1 study.30596218Chihara D, Oki YCancer treatment and researchNK-Cell Lymphomas. Cancer Treat Res. 2019; 176:163-184.Cancer Treat Res2019-01-01T00:00:002019NK-Cell Lymphomas.30370365Sheu T, Milgrom SA, Andraos TY, Gunther JR, Chi L, Nastoupil L, Fowler N, Oki Y, Fanale MA, Fayad LE, Hagemeister F, Neelapu SS, Medeiros LJ, Hosing C, Nieto Y, Ahmed S, Alousi AM, Dabaja B, Pinnix CCAdvances in radiation oncologyResponse-adapted radiation therapy for newly diagnosed primary diffuse large B-cell lymphoma of the CNS treated with methotrexate-based systemic therapy. Adv Radiat Oncol. 2018 Oct-Dec; 3(4):639-646.Adv Radiat Oncol2018-07-12T00:00:002018Response-adapted radiation therapy for newly diagnosed primary diffuse large B-cell lymphoma of the CNS treated with methotrexate-based systemic therapy.30617643Chihara D, Oki Y, Fanale MA, Westin JR, Nastoupil LJ, Neelapu S, Fayad L, Fowler NH, Cheah CYAnnals of hematologyStage I non-Hodgkin lymphoma: no plateau in disease-specific survival ? Ann Hematol. 2019 May; 98(5):1169-1176.Ann Hematol2019-01-08T00:00:002019Stage I non-Hodgkin lymphoma: no plateau in disease-specific survival ?Authorship 94082711Authorship 942178730773193An Y, Jiang W, Andraos TY, Reddy JP, Yehia ZA, Lloyd S, Duvic M, D'Souza NM, Milgrom SA, Pinnix CC, Oki Y, Smith GL, Wilson LD, Dabaja BSRadiotherapy and oncology : journal of the European Society for Therapeutic Radiology and OncologyMulti-institutional Investigation: Circulating CD4:CD8 ratio is a prognosticator of response to total skin electron beam radiation in mycosis fungoides. Radiother Oncol. 2019 02; 131:88-92.Radiother Oncol2018-12-31T00:00:002018Multi-institutional Investigation: Circulating CD4:CD8 ratio is a prognosticator of response to total skin electron beam radiation in mycosis fungoides.30519174Jensen GL, Dabaja BS, Pinnix CC, Gunther JR, Huen A, Duvic M, Oki Y, Fanale M, Hosing C, Milgrom SACase reports in oncologyRadiotherapy in Patients with Mycosis Fungoides and Central Nervous System Involvement. Case Rep Oncol. 2018 Sep-Dec; 11(3):721-728.Case Rep Oncol2018-11-12T00:00:002018Radiotherapy in Patients with Mycosis Fungoides and Central Nervous System Involvement.Authorship 9430171230919940Becnel MR, Nastoupil LJ, Samaniego F, Davis RE, You MJ, Green M, Hagemeister FB, Fanale MA, Fayad LE, Westin JR, Wang M, Oki Y, Forbes SG, Feng L, Neelapu SS, Fowler NHBritish journal of haematologyLenalidomide plus rituximab (R2 ) in previously untreated marginal zone lymphoma: subgroup analysis and long-term follow-up of an open-label phase 2 trial. Br J Haematol. 2019 06; 185(5):874-882.Br J Haematol2019-03-28T00:00:002019Lenalidomide plus rituximab (R2 ) in previously untreated marginal zone lymphoma: subgroup analysis and long-term follow-up of an open-label phase 2 trial.Authorship 94385511Authorship 9442311930718585Milgrom SA, Elhalawani H, Lee J, Wang Q, Mohamed ASR, Dabaja BS, Pinnix CC, Gunther JR, Court L, Rao A, Fuller CD, Akhtari M, Aristophanous M, Mawlawi O, Chuang HH, Sulman EP, Lee HJ, Hagemeister FB, Oki Y, Fanale M, Smith GLScientific reportsA PET Radiomics Model to Predict Refractory Mediastinal Hodgkin Lymphoma. Sci Rep. 2019 02 04; 9(1):1322.Sci Rep2019-02-04T00:00:002019A PET Radiomics Model to Predict Refractory Mediastinal Hodgkin Lymphoma.29616834Pinnix CC, Wirth A, Milgrom SA, Andraos TY, Aristophanous M, Pham M, Hancock D, Ludmir EB, Gunther JR, Fanale MA, Oki Y, Nastoupil L, Chuang HH, Mikhaeel NG, Dabaja BSLeukemia & lymphomaOmitting cardiophrenic lymph nodes in the treatment of patients with Hodgkin lymphoma via modified involved-site radiation therapy. Leuk Lymphoma. 2018 11; 59(11):2650-2659.Leuk Lymphoma2018-04-04T00:00:002018Omitting cardiophrenic lymph nodes in the treatment of patients with Hodgkin lymphoma via modified involved-site radiation therapy.Authorship 9452711730990235Pinnix CC, Dabaja BS, Milgrom SA, Smith GL, Abou Yehia Z, Nastoupil L, Romaguera J, Turturro F, Fowler N, Fayad L, Westin J, Neelapu S, Fanale MA, Rodriguez MA, Hagemeister F, Lee HJ, Oki Y, Wang M, Samaniego F, Chi L, Esmaeli BHead & neckUltra-low-dose radiotherapy for definitive management of ocular adnexal B-cell lymphoma. Head Neck. 2019 May; 41(5):1546.Head Neck2019-03-19T00:00:002019Ultra-low-dose radiotherapy for definitive management of ocular adnexal B-cell lymphoma.Authorship 9461811731029646Barta SK, Zain J, MacFarlane AW, Smith SM, Ruan J, Fung HC, Tan CR, Yang Y, Alpaugh RK, Dulaimi E, Ross EA, Campbell KS, Khan N, Siddharta R, Fowler NH, Fisher RI, Oki YClinical lymphoma, myeloma & leukemiaPhase II Study of the PD-1 Inhibitor Pembrolizumab for the Treatment of Relapsed or Refractory Mature T-cell Lymphoma. Clin Lymphoma Myeloma Leuk. 2019 06; 19(6):356-364.e3.Clin Lymphoma Myeloma Leuk2019-04-03T00:00:002019Phase II Study of the PD-1 Inhibitor Pembrolizumab for the Treatment of Relapsed or Refractory Mature T-cell Lymphoma.Authorship 946748831073068Strati P, Nastoupil LJ, Davis RE, Fayad LE, Fowler N, Hagemeister FB, Kwak L, Oki Y, Wang M, Westin J, Ruben CE, Wesson ET, Piekarz R, Fanale MA, Lee HJHaematologicaA phase 1 trial of alisertib and romidepsin for relapsed/refractory aggressive B-cell and T-cell lymphomas. Haematologica. 2020 01; 105(1):e26-e28.Haematologica2019-05-09T00:00:002019A phase 1 trial of alisertib and romidepsin for relapsed/refractory aggressive B-cell and T-cell lymphomas.Authorship 9557071431533521Hu B, Nastoupil LJ, Loghavi S, Westin JR, Thakral B, Fayad LE, Hagemeister F, Neelapu S, Samaniego F, Lee HJ, Wang ML, Fanale M, Fowler N, Oki YLeukemia & lymphomaDe novo CD5+ diffuse large B-cell lymphoma, NOS: clinical characteristics and outcomes in rituximab era. Leuk Lymphoma. 2020 02; 61(2):328-336.Leuk Lymphoma2019-09-18T00:00:002019De novo CD5+ diffuse large B-cell lymphoma, NOS: clinical characteristics and outcomes in rituximab era.Authorship 977738232037430K?hn F, Katsuragi S, Oki Y, Scholz C, Akai S, Gr?ger HChemical communications (Cambridge, England)Dynamic kinetic resolution of a tertiary alcohol. Chem Commun (Camb). 2020 Mar 07; 56(19):2885-2888.Chem Commun (Camb)2020-02-10T00:00:002020Dynamic kinetic resolution of a tertiary alcohol.Authorship 997575932824175Huen A, Haverkos BM, Zain J, Radhakrishnan R, Lechowicz MJ, Devata S, Korman NJ, Pinter-Brown L, Oki Y, Barde PJ, Nair A, Routhu KV, Viswanadha S, Vakkalanka S, Iyer SPCancersPhase I/Ib Study of Tenalisib (RP6530), a Dual PI3K d/? Inhibitor in Patients with Relapsed/Refractory T-Cell Lymphoma. Cancers (Basel). 2020 Aug 15; 12(8).Cancers (Basel)2020-08-15T00:00:002020Phase I/Ib Study of Tenalisib (RP6530), a Dual PI3K d/? Inhibitor in Patients with Relapsed/Refractory T-Cell Lymphoma.Authorship 1002838533055173Janku F, Park H, Call SG, Madwani K, Oki Y, Subbiah V, Hong DS, Naing A, Velez-Bravo VM, Barnes TG, Hagemeister FB, Falchook GS, Karp DD, Wheler JJ, Piha-Paul SA, Garrido-Laguna I, Shpall EJ, Fayad LE, Neelapu SS, Meric-Bernstam F, Kurzrock R, Fanale MAClinical cancer research : an official journal of the American Association for Cancer ResearchSafety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma. Clin Cancer Res. 2020 11 01; 26(21):5579-5587.Clin Cancer Res2020-10-14T00:00:002020Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma.Authorship 1005043633188997Schaffer M, Chaturvedi S, Davis C, de Jong J, Aquino R, Oki Y, Fourneau N, Younes A, Balasubramanian SCancer treatment and research communicationsActivity of ibrutinib plus R-CHOP in diffuse large B-cell lymphoma: Response, pharmacodynamic, and biomarker analyses of a phase Ib study. Cancer Treat Res Commun. 2020; 25:100235.Cancer Treat Res Commun2020-11-01T00:00:002020Activity of ibrutinib plus R-CHOP in diffuse large B-cell lymphoma: Response, pharmacodynamic, and biomarker analyses of a phase Ib study.Authorship 1011784933602316Johnston PB, Cashen AF, Nikolinakos PG, Beaven AW, Barta SK, Bhat G, Hasal SJ, De Vos S, Oki Y, Deng C, Foss FMExperimental hematology & oncologyBelinostat in combination with standard cyclophosphamide, doxorubicin, vincristine and prednisone as first-line treatment for patients with newly diagnosed peripheral T-cell lymphoma. Exp Hematol Oncol. 2021 Feb 18; 10(1):15.Exp Hematol Oncol2021-02-18T00:00:002021Belinostat in combination with standard cyclophosphamide, doxorubicin, vincristine and prednisone as first-line treatment for patients with newly diagnosed peripheral T-cell lymphoma.Authorship 10238141034162178Evens AM, Connors JM, Younes A, Ansell SM, Kim WS, Radford J, Feldman T, Tuscano J, Savage KJ, Oki Y, Grigg A, Pocock C, Dlugosz-Danecka M, Fenton K, Forero-Torres A, Liu R, Jolin H, Gautam A, Gallamini AHaematologicaOlder patients (aged =60 years) with previously untreated advanced-stage classical Hodgkin lymphoma: a detailed analysis from the phase III ECHELON-1 study. Haematologica. 2022 05 01; 107(5):1086-1094.Haematologica2022-05-01T00:00:002022Older patients (aged =60 years) with previously untreated advanced-stage classical Hodgkin lymphoma: a detailed analysis from the phase III ECHELON-1 study.Authorship 1026147234304287Kim WS, Oki Y, Kim SJ, Yoon SE, Ardeshna KM, Lin Y, Ruan J, Porcu P, Brammer JE, Jacobsen ED, Yoon DH, Suh C, Suarez F, Radford J, Budde LE, Kim JS, Bachy E, Lee HJ, Bollard CM, Jaccard A, Kang HJ, Inman S, Murray M, Combs KE, Lee DY, Advani R, Gunter KC, Rooney CM, Heslop HEAnnals of hematologyAutologous EBV-specific T cell treatment results in sustained responses in patients with advanced extranodal NK/T lymphoma: results of a multicenter study. Ann Hematol. 2021 Oct; 100(10):2529-2539.Ann Hematol2021-07-24T00:00:002021Autologous EBV-specific T cell treatment results in sustained responses in patients with advanced extranodal NK/T lymphoma: results of a multicenter study.Authorship 10271421934341990Landsburg DJ, Barta SK, Ramchandren R, Batlevi C, Iyer S, Kelly K, Micallef IN, Smith SM, Stevens DA, Alvarez M, Califano A, Shen Y, Bosker G, Parker J, Soikes R, Martinez E, von Roemeling R, Martell RE, Oki YBritish journal of haematologyFimepinostat (CUDC-907) in patients with relapsed/refractory diffuse large B cell and high-grade B-cell lymphoma: report of a phase 2 trial and exploratory biomarker analyses. Br J Haematol. 2021 10; 195(2):201-209.Br J Haematol2021-08-02T00:00:002021Fimepinostat (CUDC-907) in patients with relapsed/refractory diffuse large B cell and high-grade B-cell lymphoma: report of a phase 2 trial and exploratory biomarker analyses.Authorship 10590823Authorship 10546751535952327Westin J, Davis RE, Feng L, Hagemeister F, Steiner R, Lee HJ, Fayad L, Nastoupil L, Ahmed S, Rodriguez A, Fanale M, Samaniego F, Iyer SP, Nair R, Oki Y, Fowler N, Wang M, Ma MCJ, Vega F, McDonnell T, Pinnix C, Griffith D, Lu Y, Tewari S, Sun R, Scott DW, Flowers CR, Neelapu S, Green MRJournal of clinical oncology : official journal of the American Society of Clinical OncologySmart Start: Rituximab, Lenalidomide, and Ibrutinib in Patients With Newly Diagnosed Large B-Cell Lymphoma. J Clin Oncol. 2023 02 01; 41(4):745-755.J Clin Oncol2022-08-11T00:00:002022Smart Start: Rituximab, Lenalidomide, and Ibrutinib in Patients With Newly Diagnosed Large B-Cell Lymphoma.36375046Cherng HJ, Alig SK, Oki Y, Nastoupil LJ, Fayad L, Neelapu SS, Turturro F, Hagemeister F, Craig AFM, Macaulay CW, Rodriguez MA, Lee HJ, McDonnell TJ, Flowers CR, Vega F, Green MR, Feng L, Kurtz DM, Alizadeh AA, Davis RE, Westin JRBlood advancesA phase 1/2 study of lenalidomide and obinutuzumab with CHOP for newly diagnosed DLBCL. Blood Adv. 2023 04 11; 7(7):1137-1145.Blood Adv2023-04-11T00:00:002023A phase 1/2 study of lenalidomide and obinutuzumab with CHOP for newly diagnosed DLBCL.true1Associate ProfessorAssociate Professortrue1Associate ProfessorAssociate Professortrue1ProfessorProfessortrue1ProfessorProfessortrue1ProfessorProfessortrue1Associate ProfessorAssociate Professortrue1Associate ProfessorAssociate Professortrue1Assistant ProfessorAssistant Professortrue1ProfessorProfessortrue1ProfessorProfessortrue1Associate ProfessorAssociate Professor